Confidential  Imagio Reader-02 Study Protocol 
November 4, 2019 – Version 4.0 Page 1 of 28 Clinical Study Protocol  
Study Title:  Imagio Pivotal Multi -Reader, Multi -Case Study of Optoacoustic Images 
versus Imagio Ultrasound to Guide Decision to Biopsy  
Study Type:  Single arm, sequentially read, controlled, blinded, multi -reader, multi -
case study  
Study Identifier:  Reader Study -02 
Study Phase:  Pivotal  
Study Objective:  To prospectively demonstrate Imagio effectiveness for pre -defined 
endpoints  
Indication:  The Imagio® breast imaging system is indicated for use by a trained and 
qualified healthca re provider for evaluation of palpable and non -palpable 
breast abnormalities  in women who are referred for a diagnostic breast 
work -up, following clinical presentation or either screening or diagnostic 
mammography. The ultrasound mode should be initially u sed in a 
targeted fashion, to assess  any focal area(s) of clinical or imagin g 
concerns.  In ultrasound mode, the device can be used to assign a BI -
RADS category to  either breast tissue or  a mass  that is causing clinical 
or imaging concerns . Masses which are  classified as  BI-RADS 
categories 3 through 5 may then be assessed using the Opto -Acoustic 
(OA) mode. In the OA mode, the Imagio® provides information about 
the central nidus, boundary and peripheral zones to assist in the 
diagnosis of the benign or malign ant mass(es) o f interest. For 
ultrasound BI -RADS 3 -5 masses, using the OA features of the mass 
allows for improved classification of the mass of interest as compared to 
ultrasound alone. The OA mode is not indicated for ultrasound BI -RADS 
1 and 2 lesions.  
This device is  not intended to be used as a replacement for 
mammographic screening or for definitive pathologic diagnosis.  
Sponsor:  Seno Medical Instruments, Inc.  
Sponsor 
Contact:  Shaan Schaeffer, Vice President, Clinical Operations  
Seno Medical Instrume nts, Inc. 8023 Vantage Dr.  
Suite 1000  
San Antonio, TX 78230  
Phone: 210 -615-6501  
E-mail: sschaeffer@senomedical.com
IDE Approval 
Identifier  Not Applicable – Non-Significant Risk Study  
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 3 of 28 Contents  
List of Figures  ................................ ................................ ................................ ................................ .... 4 
List of Tables  ................................ ................................ ................................ ................................ ..... 4 
List of Abbreviations and Definitions of Terms  ................................ ................................ ...............  4 
STUDY TEAM LEADERS  ................................ ................................ ................................ ...................  7 
CLINICAL RESEARCH ORGANIZATIONS  ................................ ................................ ........................  7 
STUDY OBJECTIVES  ................................ ................................ ................................ .................  7 
1.1 Primary Objective  ................................ ................................ ................................ .................  7 
1.2 Secondary Objective  ................................ ................................ ................................ ............  7 
ENDPOINTS  ................................ ................................ ................................ ................................  7 
2.1 Primary Endpoint  ................................ ................................ ................................ .......................  7 
2.2 Secondary Endpoints  ................................ ................................ ................................ .................  7 
BACKGROUND AND RATIONALE  ................................ ................................ ............................  7 
Senogram  ................................ ................................ ................................ ................................ ... 8 
STUDY DESIGN  ................................ ................................ ................................ ..........................  8 
SELECTION OF READERS  ................................ ................................ ................................ ........  9 
6.1 Reader Qualification Criteria  ................................ ................................ ................................ ...... 9 
6.2 Reader Training  ................................ ................................ ................................ .......................  10 
SELECTION OF READER SETS  ................................ ................................ ..............................  11 
7.1 Inclusion Criteria  ................................ ................................ ................................ ................  11 
7.2 Exclusion Criteria  ................................ ................................ ................................ ...............  11 
7.3 Reader  Set Selection Procedure  ................................ ................................ ........................  11 
READER STUDY PROCEDURES  ................................ ................................ .............................  11 
8.1 Reader Study Process Work Flow  ................................ ................................ ......................  11 
8.2 Schedule of Reader Sessions  ................................ ................................ ............................  13 
8.3 Description of Read ing Environment  ................................ ................................ ..................  13 
8.4 Randomization  ................................ ................................ ................................ ...................  14 
8.5 Blinding  ................................ ................................ ................................ ..............................  14 
SAFETY ASSESSMENTS  ................................ ................................ ................................ .........  14 
STATISTICAL CONSIDERATIONS ................................ ................................ ...........................  14 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 4 of 28 
 10.1  General Design Issues  ................................ ................................ ................................ ....... 14 
10.2  Reader / Image Set Sample Size  ................................ ................................ .......................  15 
10.3  Additional Hypothesis Tests  ................................ ................................ ...............................  17 
10.4  Population Definit ion ................................ ................................ ................................ ..........  17 
10.5  Interim Analysis  ................................ ................................ ................................ ..................  17 
10.5.1  Plan ................................ ................................ ................................ ............................  17 
10.5.2  Methodology  ................................ ................................ ................................ ...............  17 
10.5.3  Timing  ................................ ................................ ................................ ........................  18 
10.5.4  Execution  ................................ ................................ ................................ ...................  18 
10.6  Protocol Deviations  ................................ ................................ ................................ ............  19 
10.7  Outcomes  ................................ ................................ ................................ ...........................  19 
10.8  Hierarchical Testing ................................ ................................ ................................ ............  19 
10.9  Data Analyses  ................................ ................................ ................................ ....................  19 
 Graphical InterFACE For BI -RADS CATEGORY and POM RATING  ................................ ...... 20 
 DATA COLLECTION AND QUALITY ASSURANCE  ................................ ................................  21 
12.1  Data Manage ment  ................................ ................................ ................................ ..............  21 
12.2  Quality Assurance  ................................ ................................ ................................ ..............  21 
12.2.1  Training  ................................ ................................ ................................ ......................  21 
12.2.2  Quality Control  ................................ ................................ ................................ ............  21 
12.2.3  Monitoring ................................ ................................ ................................ ...................  21 
 PARTICIPANT RIGHTS AND CONFIDENTIALITY  ................................ ................................ ... 21 
13.1 Informed Consent Forms  ................................ ................................ ................................ ....... 21 
13.2 Participant Confidentiality  ................................ ................................ ................................ ....... 22 
13.3 Study Discontinuati on ................................ ................................ ................................ ............  22 
 PUBLICATION OF RESEARCH FINDINGS  ................................ ................................ ..............  22 
 REFERENCES  ................................ ................................ ................................ ..........................  22 
 VERSION HISTORY  ................................ ................................ ................................ ..................  23 
 
 
LIST OF FIGURES  
Figure 1: Likelihood of Malignancy  ................................ ................................ ................................ .. 8 
Figure 2; Reader -02 Pivotal Study Work Flow  ................................ ................................ ...............  13 
Figure 3:  Graphical input of BI -RADS category and POM rating  ................................ ..................  21 
 
LIST OF TABLES  
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
ACR  American College of Radiology  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 5 of 28 
 AE Adverse Event  
ANOVA  Analysis of Variance  
AUC  Area Under the Curve  
BBRF  Boston Biostatistics Research Foundation  
BI-RADS  (BR) Breast Imaging -Reporting and Data System  
CB Color Balancing  
CDU  Conventional Diagnostic Ultrasound  
CI Confidence Interval  
CSR  Clinical Study Report  
eCRF  Electronic Case Repo rt Form  
EDC  Electronic Data Capture System  
eTMF  Electronic Trial Master File  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
GEE  Generalized Estimating Equations  
HIPAA  Health Insurance Portability and Accountability Act  
IA Interim Analy sis 
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IRB Institutional Review Board  
ITD Intention -to-Diagnose  
IUS Imagio Internal Ultrasound  
LOM  Likelihood of Malignancy  
MQSA  Mammography Quality Standards ACR  
MRMC  Multi -reader, multi -case  
N/A Not Applicable  
NLR Negative Likelihood Ratio  
NPV Negative Predictive Value  
NSR  Non-significant Risk  
OA Opto -Acoustic  
OR Obuchowski -Rockette  
PD Protocol Deviation  
PDU  Positive Diagnostic Ultrasound  
PDUNB  Positive Diagnostic Ultra sound, No Biopsy  
PIONEER  Abbreviated name of a previous study (Pivotal study of Imaging with Opto -
acoustics to diagnose breast masses detected by mammography and/or clinical 
findings: A New Evaluation Tool for Radiologists)  
PLR Positive Likelihood Ratio  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 6 of 28 
 PMA  Premarket Approval  
POM  Probability of Malignancy  
PPV Positive Predictive Value  
QC Quality Control  
ROC  Receiver Operating Characteristic  
ROI Region of Interest  
SAP Statistical Analysis Plan  
SAS Statistical Analysis System  
SG SenoGram  
SOP  Standard Operating Procedure  
SSRE  Sample Size Re -Estimation  
TPB Truth Panel Benign  
TRIAD  Transfer of Images and Data  
USA United States of America  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 7 of 28 
 STUDY TEAM LEADERS  
Shaan Schaeffer - VP of Clinical Operations  
Philip Lavin PhD, FASA, FRAPS - Chief Biosta tistician  
Tom Stavros MD, FACP - Chief Medical Officer  
CLINICAL RESEARCH ORGANIZATIONS  
American College of Radiology Center for Research and Innovation  (ACR - CRI) will serve as the 
Imaging Core Lab to conduct t he Imagio Pivotal Reader Study. ACR -CRI is l ocated in  
Philadelphia, PA 19103. ACR -CRI complies with Good Clinical Practices (GCPs) and Title 21 
Code of Federal Regulations (CFR) Part 11.  
Boston Biostatistics Research Foundation (BBRF) will provide study d esign, mass sampling, 
database construction,  and data analyses for the Imagio Pivotal Reader Study. BBRF is located in 
Framingham, MA.  
 
 STUDY OBJECTIVES  
1.1 Primary Objective  
To evaluate the following overall and for individual readers for IUS versus Imagio ( IUS+ OA):  
The gain in Imagio (Imagio Intern al Ultrasound [IUS] + Opto -acoustic [OA]  specificity versus 
IUS, controlling for sensitivity  
1.2 Secondary Objective  
To evaluate overall and for individual readers for IUS versus Imagio (IUS +OA): additional 
effectiveness performance metrics of interest.  
 ENDPO INTS  
2.1 Primary Endpoint  
To evaluate  the following overall and for individual readers for IUS versus Imagio (IUS+OA ):  
A clinically significant gain  of 10%  in specificity for 98% sensitivi ty associated with Imagio 
(IUS+OA ) compared to IUS, with specifici ties interpolated from the respective ROC curves as 
required.  
 
   2.2 Secondary Endpoints  
The following secondary endpoints will be evaluated overall and by individual readers:  
• Negative Lik elihood Ratio defined as ((1 -sensitivity)/specificity)  
• Positive Li kelihood Ratio defined as (sensitivity/(1 -specificity))  
• Partial ROC AUC corresponding to 9 5-100% sensitivity  
 
 BACKGROUND AND  RATIONALE  
The Imagio Reader -02 Pivotal Study is intended to evaluate if the results observed in the 
previous Reader -01 Feasibility Study can be confirmed for pre -specified effectiveness 
endpoints.  Using Intention -to-Diagnose (ITD) masses from the PIONEER Pivotal Study, 480 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 8 of 28 
 to 840 masse s are to be used for the Reader -02 Pivotal Study, the remaining masses will be 
reserved for training  the SenoGram tool.   
 SENOGRAM  
The S enoGram  is a tool that helps the radiologist predict the likelihood of malignancy (LOM) 
based on a set of reader -assigne d feature scores and other relevant data.  The S enoGram  
classification model was validated and locke d prior to the Reader -01 Feasibility Study. The 
algorithm, feature set, and development method remained locked for the Reader -02 Pivotal 
study.  The SenoGram  model  will be refit to a subset of the PIONEER dataset that excludes all 
masses in the Reader -02 Pivotal study.  The refit model will be  locke d prior to the beginning of 
this Reader -02 study. For this Reader -02 study, the S enoGram  tool will consist of two 
components, a user interface and a back -end computation engine.   
The reader will enter 5 feature score s for IUS , 5 feature scores for OA and 4 other features : 
subject age, maximum diameter depth to posterior wall of mass, and mammographic BI -RADS 
category  (when available) . When all data has been entered the user interface will graphically 
display the SenoGram  LOM . 
The reader will then enter his/her final  assessments in the following order  after viewing the 
SenoGram LOM based on his/her knowledge from experience and IUS+OA  training:  
1. Probability of Malignancy (POM) and  
2. Subsequent BI -RADs category  
The S enoGram  output figure is shown below.  The S enoGram  back -end uses an ensemble of 
models to compute a set of predicted probabilities. The mean of these predicted probabilities 
is indic ated by the blue circle, and the 5% to 95% prediction interval is depicte d as a blue 
horizontal line through the circle.  For reference purposes the S enoGram  prediction is shown 
relative to the suggested biopsy/no -biopsy threshold, depicted by a black vertical line on the 
left side of the bar.  This threshold corresponds to an estimated 2% false negative rate (i.e., 
98% sensitivity).   The S enoGram  uses machine learning to assist the radiologist in 
assimilating and weighting 1 4 features  that impact the LOM .  
 
 STUDY DESIGN  
This will be a single arm, controlled, blinded, multi -reader, multi -case (MRMC) study using a 
sequential design.  The study will include 15 readers with an additional 5 back -up readers. 
Readers that participated in the Seno PIONEER  Study , the MAESTRO Study,  or the Reader -
01 Feasibility Study are not eligible to  participate as readers in this Reader -02 Pivotal Study.  
Imagio (IUS+OA) training will be completed prior to any reads taking place. Read 1 will be 
immediately followed by Rea d 2 within the same read session.  
Figure 1: Likelihood of Malign ancy 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 9 of 28 
 • Read 1 (Control): History + Mammogram (if avail able) + IUS (stills and videos 
provided), IUS Probability of Malignancy (POM) and BI -RADS category  assigned  in the 
data form  then locked.  
• Read 2 (Test): History + Mammogram ( if available) + IUS (stills and videos provided), 
and Imagio (IUS+OA)  (stills and  videos provided).  Imagio (IUS+OA) POM and BI -
RADS  category assigned  after viewing the  SenoGram (SG)  output. The data  form is 
then locked.     
Read 1 reflects the typical information available to a radiologist when evaluating standard 
ultrasound images, t aking into consideration the mass , patient history and assessing 
mammogram BI-RAD S results , when available. The History details provided are sum marized 
under the Blinding section of the protocol. Read 1 (IUS reads) will serve as the control . 
Read 2 will di splay the  IUS + OA images.  Each  reader will record IUS and OA feature scores 
within the case report form and the S enoGram  will display a predic tion interval based upon the 
reader feature score input. Each  reader will first assign final POM and then a BI-RADS score.  
At this point , the Read 2 form is locked.   
The Reader -02 Pivotal Study will consist of between  480 to 840 masses with complete 
imag ing read sets from the original PIONEER Intention -to Diagnose (ITD)/analysis population.  
The masses will be ran domly selected from within the PIONEER Study.  The data will be 
organized in blocks of 120 masses, each consisting of 72 benign plus 3 high risk  (to be 
categorized as benign) and 45 malignant masses (reflecting the same 37.5% prevalence of 
cancer as the ov erall PIONEER  ITD/analysis population) . The masses were classified by 
conventional diagnostic ultrasound (CDU) as BI -RADS 3 to 5 and will be  selected at random in 
proportion to the original assignment distribution of BI -RADS classifications among subjects in 
the PIONEER Study. To facilitate the alignment of the PIONEER Pivotal Study data with the 
Reader 02 Pivotal Study data, the mass image set sa mpling plan will select a benign mass 
proportion with and without mammograms depending on availability of the ma mmograms; this 
stratification will not apply for malignant masses where nearly all masses were previously 
evaluated using mammography.  Blocks o f 120 masses will be used for the effectiveness 
endpoint analyses with a  blinded interim analysis conducted afte r all readers evaluate 360  
(360-10 color balance masses= 350)  masses with sample size re -estimation  used to possibly 
increase the sample size up to 840 masses depending on the underlying reader variability 
driving sample size for the primary effectiveness endpoint.  A total of 29  image sets  used to 
tune the  color balance algorithm  (among the 840 masses)  will be replaced with 29 comparable  
image sets in accordance with the Reader -02 Mass Sampling Plan  for purposes of the final 
analysis ; these replacement ma sses will come from the set of 60 overage masses from the 
PIONEER Pivotal Study plus masses from th e PIONEER Pilot Study  if there are insufficient 
overage cases.   
 SELECTION OF READERS  
  6.1 Reader Qualification Criteria  
• Completed residency and are board certified in radiology  
• Active breast imager for at least 3 years.  
• Readers to meet mammography interpretation requirements per Mammography 
Quality Standards ACR (MQSA) for the year prior to study  
• Readers to meet breast imaging ultrasound interpretation req uirements per ACR for 
year prior to study  
• For the clinical study, a willingness to use BI -RADS 4 sub -categories  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 10 of 28 
 • For the clinical study, the ability to participate and read all masses in both IUS and 
IUS+OA  reader sessions  
   6.2 Reader Training  
Imagio (IUS +OA) Training Summary R eader 02 Pivotal Study  
 
1.     Didactic training module   
a) Fundamentals of OA  (Questions and Answers)  
b) OA feature scoring  (Questions and Answers)  
c) Brief summary of Seno learnings from previous studies  
d) OA-histologic correlation and False  Positive cases  (Questions and Answers)  
e) OA artifacts (Questions and Answers)  
f) IUS feature scoring, including importance of BI -RADS 4 subcategories, NLR and 
Bayes Theorem  (Questions and Answers)  
g) PIONEER Pivotal Study False Negative analysis (Questions and An swers)  
h) The Seno Gram and how to use It 
i) Summary  (final questions and comments)  
2.    Interactive reading training case module  (up to 30 cases)  
a) Mixture of benign and malignant cases enriched to 50% malignant  cases  
b) Mixture of cases with good, average, and belo w average PIONEER reader 
performance – will start with easy cases, move to average cases, and finish with most 
difficult cases . 
c) Readers will learn to use a reading station, draw regions of interest ( ROIs ), score  IUS 
and OA features, use the SenoGram to aid in predict ing OA POM and BI -RADS 
category  
d) Each case will be read and scored by the reader  trainees. The Seno instructor will 
review how and why he/she would score the case.  Case histology will be reviewed 
and discussed with concordance or discordance of  OA feature scoring.  
3.   Test Cases - 30  
a) Mixture of benign (18) and malignant (12) masses, same prevalence as overall  
PIONEER  ITD population  
b) Mixture of easy, average, and difficult cases based upon PIONEER Pivotal Study 
reads  
 
4.  Pass / Fail criteria  
Readers reading must pass a proficiency test involving the scoring and interpretation of 30 
cases before starting their study reads. If this is not achieved the first time,  then the  reader 
takes the test  a second time . The reader will be given remediation training targeted to the 
masses for which the y made errors within the first 30 case test set, and the reader will be 
given a second opportunity to take the test on a different set of 30 test cases. If a reader 
fails the second test, remediation will take p lace before they start the Reader -02 Pivotal 
Study reads.  The reader will proceed to read Reader -02 pivotal cases whether or not they 
pass the second test  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 11 of 28 
 
 SELECTION OF READER SETS  
7.1 Inclusion Criteria  
Reader sets must meet all the following inclusion crite ria to be included in this study:  
• One analyzable mass per patient: BI -RADS 3 , 4a, 4b, 4c , and 5 masses as declared by 
clinical site investigator via PIONEER study inclusion criteria and categorized as BIRADS 
3, 4a, 4b , 4c, and 5 by conventional diagnostic ultrasound (CDU)  
• Masses declared to be in the PIONEER ITD/analysis population, including  high risk cases 
per original PIONEER protocol  
• Patient age, indication for study entry and available medical history  
• Evaluable mammograms  (when available)  and IUS and OA  video loops and still images 
for each mass    
7.2 Exclusion Criteria  
Reader image sets must be excluded if any of the following criteria are met:  
• Critical missing IUS or OA still image and/or video loop views or incorrect IUS or OA stills 
and video  loops  that would preclude  a case from being evaluated by readers  
• Reader -02 Proficiency Te st and training cases  
7.3 Reader  Set Selection Procedure  
• BBRF will develop and apply  the Mass Sampling Plan which takes  training cases and 
stratification  requirements into consi deration  
• BBRF w ill prepare the mass read order  per block to be the same for all readers  
• All image sets will be de -identified  
 READER STUDY PROCEDURES  
8.1 Reader Study Process Work Flow  
Figure 2 below illustrates, at a high level, the central reader study proc ess flow. Seno Medical 
will electronically transfer image sets to ACR -CRI. Upon receipt of the images at ACR CRI, 
imaging support staff will upload images to Transfer of Images and Data [TRI AD], ACR’s 
electronic image submission tool.  
The images automatic ally undergo a de -identification process in TRIADTM, whereby all 
personal identifier DICOM tags in the image metadata are de -identified according to 
TRIADTM’s anonymization profile. If any p ersonal identifiers are burned into exams received, 
ACR CRI staff will remove that by pixel cleaning. ACR -CRI imaging technologists will first 
perform quality control (QC -1) to document an inventory of all exams and their attributes.   
ACR -CRI’s contracted  multiple mass quality control reviewer will assess the image sets  (QC-
2) for inclusion and exclusion as well as identifying and labeling Mass 1 on all modalities 
submitted for a given subject case. The acceptable image sets from the ACR QC (QC -1 and 
QC-2) process will be incorporated  by BBRF and considered ready for cen tral read.  
BBRF is solely responsible for the selection of all masses and will generate the randomized 
study mass list  in accordance with the Mass Sampling Plan . The order of masses per blo ck 
will be the same for each participating reader.   
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 12 of 28 
 The QC -1 and QC-2 checks will be documented in study specific procedure documents and 
outputs of such checks documented on study specific forms, all of which will be archived in an 
electronic Trial Maste r File (eTMF) and ACR CRI clinical databases.  
ACR research staff s erving as read monitors will be present during read sessions to ensure 
the read sequence is maintained, eCRFs are fully completed by the reader, cross -check the 
assigned read list with compl eted eCRFs and assist in any workstation -related questions. 
Each r eader will be separately proctored by read monitors to ensure that no technical issues 
arise,  and that reader scoring is independent.  The read monitors will relay any issues 
recognized from the readers or monitors they cannot resolve to the ACR Project Ma nager for 
remediation.  
A manual process of data entry will be performed. In order to maximize both workflow 
efficiency and data integrity, this process will be achieved by using the combination of the 
reader and a read monitor, working together as a team.  Both the reader and the read monitor 
will be trained on the data entry process prior to production subject case assessments.  The 
process of data entry is outlined below.   
1. Read m onitor calls out the Read ID to be reviewed based on the provided Reader W ork 
List. The reader opens the Subject image case in the image viewing workstation. The read 
monitor opens the Subject eCRF case in the Rave Electronic Data Capture (EDC) 
Database. T he reader calls out the Subject ID for the opened case as confirmation tha t it 
corresponds to the Subject ID opened in the eCRF database by the read monitor.  
2.   Reader performs the specified subject’s image review using the designated Workstation 
and fol lowing assessment criteria as trained on for this study.   
3. Read monitor  prepares to perform data entry for the specified subject.  
4. When the reader is ready to provide the data for data entry, the reader verbally notifies the 
read monitor.  
5. The reade r verbally provides the answers to each of the eCRF required field entries . 
6. As the read monitor performs the manual data entry for each of the sequential fields 
directed by the flow of the eCRF, the read monitor verbally calls out their entry which is 
then verbally confirmed (or corrected, as necessary) by the reader.  
7. This process will be repeated until all the appropriate fields in the eCRF for each of the 
subject  cases  are completed.  
The reader electronically signs off on the data for a subject case  at the completion of his/her 
review. It is understood that the commitment  of a reader’s electronic signature on the eCRF 
signifies that the assessment of the corresponding randomization ID is complete and accurate 
and is an attestation that no changes/edi ts need to occur.  
The read monitor should be attuned to reader performanc e and suggest breaks as necessary 
to avoid reader fatigue.   
As per the image review and data entry workflow described in this Protocol, once a subject 
scan review is completed by a reader, the reader provides their electronic signature and the 
eCRF is ‘lo cked’, preventing further changes.  
Upon completion of all central read assessments by all readers, ACR -CRI will post the results 
to ACR’s secure portal, BBRF will have access to the portal for purposes of conducting the 
statistical analyses following datab ase locks for the interim and final analyses.   
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 13 of 28 
 Figure 2; Reader -02 Pivotal Study Work  Flow  
 
 
8.2 Schedule of Reader Sessions  
All reads will include standard reader training on an image viewing workstation including a 
mammography monit or as well as training on  eCRF completion within the Medidata RAVE 
Electronic Data Capture ( EDC ) system, etc.  
Imagio (IUS+OA) training, which incl udes training on the SenoGram,  and a proficiency test will 
take place prior to the start of all study reads.  
Readers read blocks including IUS and Imagio (IUS+OA) reads in sequential order in 
accordance to their schedule and read speed.  
8.3 Description of Read ing Environment   
After completion of standard training and Imagio (IUS+OA)  training, each of the readers wil l 
use an image display and electronic data capture workstation to perform image analysis, 
working alongside an ACR read monitor, for all reading ses sions. Each reader and read 
monitor will be in a designated, private reading room for their use during a rea ding session. 
Readers will work undistracted so that their attention is focused on an accurate interpretation. 
The workstation desk will have adjust able height for reader comfort, the room will be equipped 
with noise abatement features, diagnostic display monitors and moderate illumination. As part 
of reader training and as documented in the confidentiality agreement they sign during the 
ACR CRI contr acting process, readers will be aware and monitored to maintain confidentiality 

 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 14 of 28 
 on study details and subject  images reviewed. Access to the reading rooms is controlled and 
read monitors ensure readers do not take any unauthorized material into the reading rooms.  
8.4 Randomization  
BBRF will generate the randomly selected read list.  The read order will be the same fo r all 
readers  within each block  of 120 masses presented .  
 
8.5 Blinding  
The identification of cases randomly selected from the PIONEER dataset to includ e in the 
study, as well as the original reader results for those cases, will be blinded to all Seno 
personne l except individuals directly involved in the study.  The assigned unblinded statistician 
responsible for performing the planned interim analysis wi ll be the only individual to have 
access to the interim Reader -02 Pivotal Study analysis results.   
The reade rs will be blinded to the diagnosis, but the reader will have access to the following 
baseline variables:  
• Age 
• Indication (reason study was ordered)  
• Mass location   
• Medical History as available  
• Mammograms (if available).  
Readers will also not have access t o results from other readers or to the original biopsy or 
follow -up outcomes during the study.  
 SAFETY ASSESSMENTS  
Safety assessments are not required as this is a reader study of de -identified Imagio (IUS+OA) 
and IUS images. No patient diagnoses are affec ted by the reader sets or this MRMC study.    
 STATISTICAL CONSIDERATIONS  
10.1 General Design Issues   
BBRF will implemen t the Reader -02 Pivotal Study Mass S ampling Plan to  randomly select 
masses .   
The unit of measurement for reader -based outcomes is at the rea der-mass level. The Reader -
01 Feasibility Study demonstrated that readers could conduct POM evaluation separately for 
IUS and then for Imagio (IUS+OA ) (primary) to evaluate the primary and secondary 
effectiveness endpoints.   
The primary endpoint is to show  a specificity advantage for fixed 98% sensitivity  (OR-DBM) ; 
this diffuses the tradeoff between FNs and  FPs if the FN rate is the same. The sensitivities and 
specificities will be calculated overall and per reader using generalized estimating equations 
(GEE) and the analysis of variance (ANOVA) modeling as well as for observed without 
adjustment.   
For each  primary and secondary endpoint, Imagio  (IUS +OA ) data will be compared to IUS 
data, with the analysis stratified by the availability/non -availability of  mammogram images.  
The specificity advantages will be computed for fixed sensitivity (e.g. , 98% target)  with 
interpolation used by calculating the specificities and sensitivities from the estimated ROC 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 15 of 28 
 curve as needed. This same principle will be used to c onstruct the partial ROC curves and to 
compute the area under the ROC curve over 95-100% sensitivity. Specificity at fixed sensitivity 
and partial AUC will be determined from parametric ROC curves constructed using techniques 
such as binormal or PROPROC mo dels.  
The supporting statistical methodology ( 2-8) relies on publications by Hillis, R ockette, 
Obuchowski, and Metz in accordance with best regulatory statistics practice.   Readers will be 
treated as correlated and as random effects.  
The Reader -01 Feasibi lity Study results were used to determine the Reader -02 Pivotal Study 
sample size. The  overall difference in specificity for fixed 98% sensitivity will be assessed to 
judge if the Reader -02 Pivotal Study can be conducted with 80% power to detect a 10% 
abso lute advantage in specificity (alternative hypothesis) v ersus no absolute advantage (n ull 
hypothesis) with two -sided 5% Type I error where both readers and masses (image sets) are 
considered to be random effects; this approach leads to the most conservativ e test given that 
it is based on the largest source of inter -reader variability. Reade r-01 Feasibility Study data will 
not be used or combined with any subsequent Reader -02 Pivotal Study data.  
A blinded interim analysis is planned after all readers complet e and record their findings for 
360 (360-10 color balance masses=350)  masses (first three blocks) with the final analysis to 
be conducted after 480 to 840 image sets are read; the final sample size will  depend upon the 
intra- and inter -reader variability.  Ten color balanced masses will be excluded from the interim 
analysis.  The interim analysis will assess the intra - and inter -reader variabilities in order to 
determine the final sample size (up to 840 masses).  This is not an adaptive study; under no 
circumstances will the null hypothesis, the alternative hypothesis, population of masses, or 
choice of endpoint be modified as a result of the interim analysis.   
 
10.2 Reader / Image Set Sample Size  
The sample size will be based on the primary effectiveness endpoi nt, namely the gain in 
specificity for fixed 98% sensitivity.  This calculation depends upon the number of image sets 
(one per mass) to be read, the number of readers, as well as the inter -reader variab ility 
associated with the underlying models used for a nalysis.  
The test of the primary hypothesis is powered to detect a 10% absolute specificity advantage 
(superiority) as the alternative hypothesis with no specificity advantage as the null hypothesis.  
The primary endpoint will be evaluated in the following  testable hypotheses:  
 
H0:  S Imagio = S IUS 
H1:  S Imagio ≠ S IUS 
where SImagio and S IUS   represent specificity,  values associated with Imagio (IUS + OA) and 
IUS. 
The sample size calculations conservatively assume that  both readers and masses are 
random effe cts; an ANOVA model will be used to compute sample size .  The sample size was 
computed using the following statistical software written by Stephen Hillis and entitled: Multi -
Reader Sample Si ze Program for Diagnostic Studies [http://perception.radiology.uio wa.edu.].    
For 80% power, a two -sided hypothesis test with a two -sided 5% alpha, and 15 readers, a 
sample size of 854 image sets is needed to detect a 10% absolute advantage in specificity for 
Imagio (IUS + OA) vs IUS , assuming a fixed 98% sensitivity and  the same intra - and inter -
reader standard deviation observed in the Reader -1 Feasibility Study.  
The supporting calculations including the software output follow:  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 16 of 28 
  
Initially, 360 masses will be read by all readers  for the purposes of performing the inter im 
analysis to assess the sources of variation and to rerun the sample size estimate for the 
primary effectiveness endpoint .  Neither futility nor efficacy will be assessed; this is not an 
adaptive design.   
The sample size may be increased from the minimum  of 480 image sets to a maximum of 840 
image sets (7 complete blocks)  in increments of 120 masses p er block .  All original color 
balance masses will be  replaced  with comparable masses and image sets within the final 
analysis  from the PIONEER Pivotal overag e masses .  
The maximum sample size to be used for the study will be capped at 840 masses.   An 
overage mass set will be set aside in case quality control issues are found with the images 
and replacement  masses are needed.  After excluding the pool of 840 m asses and overage  
masses , approximately 900 masses will remain for independent SenoGram training.  No 
masses used to train the SenoGram , will be in the pool of 840 study masses plus 
overage.    We have removed the 29 masses from the pool of study masses whi ch were 
mistakenly included from the original color balance algorithm.  
Every effort will be made to identify missing reader generated data in real time.  Each block of 
120 masses will include 75 benign (72 benign + 3 high risk) and 45 malignant masses to 
represent t he PIONEER study.   
With the exception of masses excluded due to protocol deviations, all complete reads will be 
included in all analyses, consistent with an “Intention -to-Diagnose” approach.  

 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 17 of 28 
 10.3 Additional Hypothesis Tests  
The following two-sided hypothesis tests will be applied using the observed estimates for NLR 
and PLR  as well as using the PROPROC for the partial ROC AUC : 
 
• NLR:  
o H0: NLR IUS = NLR Imagio vs 
o HA: NLR IUS ≠ NLR Imagio  representing a  reduction  
• PLR:  
o H0: PLR IUS = PLR Imagio vs 
o HA: PLR IUS ≠ PLR Imagio  representing a n increase  
• Partial ROC AUC:  
o H0: pAUC IUS = pAUC Imagio vs 
o HA: pAUC IUS ≠ pAUC Imagio  representing a n increase  
Hierarchica l testing will be appli ed to se ek labeling claims if warranted by the pre -defined  
testing procedure  (see Section 10.8) .   
 
10.4 Population Definition  
Masses and images will be selected for use in accordance with the study protocol, inclusion 
and exclusion criteria.   
10.5 Interim Analysi s 
10.5.1  Plan  
The interim analysis (IA) is to re-estimate sample size to avoid running an underpowered  
study . The IA will be performed by an unblinded statistician. The  Sponsor and all other parties  
will remain blinded to  the results.  The only communication to the  spons or will be the fina l  
sample size recommendation.  The sample size may be increased up  to 840 masses from the  
initial 480 masses in increments of 120  masses per block in order to achieve 80% power for   
the primary  endpoint . This recommendation w ill be b ased solely on  variance parameters re - 
estimated in  the IA (but not the effect size). Thus, these IA results fall into the category of non - 
comparative  results .  Thus, the IA ha s negligible effect on the Type 1 error.  The IA w ill be  
based on the  total variance estimate  (inclusive of both reader and  imaging modality variations)  
so, the IA remains 'non -comparative' since the interim treatment effect was not used to  
compute the final sample  size. 
 
10.5.2  Methodology  
The sole IA goal is to compute the final sa mple si ze based on the primary endpoint.  The 
samp le size re -estimation (SSRE) will be performed without any adaptation.  SSRE will  be 
conducted to detect the pre-planned 10% absolute advantage in specificity for fixed 98% 
sensitivity , given that this  is an estab lished criterion agreed upon with FDA.  The standard 
deviation (from reader as a random effect) is not known.  There w ill be no preplanned or 
performed assessments for futility, stopping for early efficacy, dropping readers, altering the 
pre-planned 10% ef fect hypothesis, or any other adaptation.  Therefore, this is classic SSRE.   
 
Huang and Chen (1) references this application as distinct from their discussion of adaptive 
designs.  Our IA is based entirely on non -comparative data, that is, no information about 
treatment effects were incorporated into the decision process.  For this SSRE situation (a non -
comparative interim), it can be shown that performing analyses at the conventional one -sided 
0.025 significance level has a negligible effect o n the Type 1  error probability (FDA Guidance 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 18 of 28 
 on Adaptive Trials  (2), Wittes ( 3), Kieser and Friede ( 4), Friede and Kieser ( 5), among others).  
Wittes advises that the alpha spend is small when the observed variance is less than the 
assumed variance (as per  the interim  analysis) without accounting for imaging modality.  
Huang and Chen advise that the alpha spend is small when the conditional power exceeds 
60% which is the case when a 10% delta is assumed; any delta effect would further reduce the 
reader vari ance.  Thus,  the alpha spend for conducting the planned interim analysis is small.  
 
From a testing perspective, the conclusions should hold in recognition that the p -value is a Z-
score whether derived from a one -sample or a two -sample test independent of t he model use d 
(Huang  or Hillis).  All alpha adjustment depends on a linear combination of Z -scores ( 6) for 
respective Z -scores prior to and after the pre -planned interim analysis.  Thus, first principles all 
lead to the conclusion that the alpha spend is s mall enough to ignore.  Our estimate is that the 
alpha spend is no more than 0.01% under the given conditions.  The minimal alpha spend 
derives from the abundant two -sample literature to apply to our paired sample setting with no 
published literature.      
 
10.5.3  Timin g 
The single blinded interim analysis is planned once 360  (360-10 color balance masses=350)  
completed image sets are read by each reader and the data become available.  The interim 
analysis will be performed by an independent, unblinded third party statistician  who will make 
recommendations below to Seno Medical Inc. based on the results from this initial cohort of 
masses:  
1. Sample Size  Calculation:  
___One  additional  block  is required  (480 masses ) OR 
___Two  additional blocks  are required   (600 masses)  OR 
___Three  additional  blocks  are required  (720 masses)  OR 
___Four  additional  blocks  are required  (840 masses)  OR 
___Four additional blocks  (840 masses)  are not sufficient but  reads should continue 
because there is a reasonable chance to reach statistical significanc e based on 
the conditional power assuming the alternative hypothesis holds.  
___Four additional blocks (840 masses) are not sufficient, reads should not continue  
because there is not a reasonable chance to reach statistical significance based on the  
conditi onal power assuming the alternative hypothesis holds.  
 
To maintain blinding to the interim results, no specific results from the interim analysis will be 
shared by the unblinded party performing the analysis with Seno or any other study 
participant, and on ly one of the above recommendations will be provided.  Seno retains the 
right to accept, not accept, or modify any recommendation concerning changes to conduct of 
the study.  
There are no plans to stop the study early for benefit or a positive outcome on t he basis of the 
interim analysis results.  No alpha wil l be spent to perform this interim analysis since this 
analysis is for sample size re -estimation  only (1).  Under no circumstances will the alternative 
hypothesis be modified as a result of this analys is.  The final analysis will include the results 
from t he n=360  (360-10 color bal ance masses=350)  interim analysis.    
10.5.4  Execution  
The unblinded biostatistician will only  evaluate the overall SD which was the nuisance 
parameter driving sample size for the fi xed 10% difference to be detected.  The unblinded 
biost atistician will not ne ed to take the observed delta  into account .  Other than the preplanned 
sample size calculation to determine the remaining blocks required to complete the study, no 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 19 of 28 
 other informati on will be revealed to the Sponsor or to any other members of the analysis 
team.  Th e IA will be  executed to the blinde d principle.  
 
10.6 Protocol Deviations  
The protocol deviations will be reviewed in advance of the interim and final analyses  for any 
unreadabl e, unevaluable, or skipped image sets .  A Protocol Deviation Meeting will be held 
among results -blinded parties prior to the preplanned n=360 interim analysis and final analysis 
to address how to handle impacted image sets .     
At study completion, the num ber and type of protocol deviations will be  presented overall and 
by reader to determine whether there are statistical concerns. The biostatistician will report 
findings to the study sponsor.  
10.7 Outcomes  
Outcomes will be analyzed according to the PIONEER Tr uth Panel findings and th e pathology 
diagnosis (if available) as truth; Truth Panel Benign (TPB) will be a benign diagnosis.  The final 
analyses will be performed following database lock.   
10.8 Hierarchical Testing  
To extend labeling claims beyond the primary e ndpoint, a hierarchical t esting strategy will be 
used to control Type 1 error associated with testing the primary endpoint and three secondary 
endpoints in the following pre -defined order until statistical significance is no longer reached in 
support of ex tended labeling:  
• Increase  in specificity for fixed 98% sensitivity.  
• NLR 
• PLR 
• pAUC over 95% to 100% sensitivity  
No other endpoints are to be included as labeling claims.  
  
10.9 Data Analyses  
All analyses will be performed in a GCP -controlled environment using the Hillis software (see 
references 3 -7), SAS v9.3 or higher , and StatXact v10 or later unless otherwise specified.   
See the companion SAP for further details.  
All significance testing will be two -sided; results will be presented using two -sided p -values 
and two-sided 95% confidence intervals.   
All final analyses will exclude the 29 Color Balanced masses; 350 masses will be analyzed at 
the interim analysis  timep oint. This excludes the 10 Color Balance masses. For the final 
analysis, t he 29 Color Balanced mas ses will be replaced from the overage and the PIONEER 
Pilot Study if there are insufficient masses among the overage  masses .    
Methods of analysis will be ba sed on MRMC analysis methods by Obuchowski and Rockette 
where both reader and mass are random effe cts (see references  7-13). Two -sided 95% 
confidence intervals will be computed for the individual outcomes (IUS, Imagio  (IUS+OA) ) and 
paired differences.   
The same approach will be used to compute the differences in partial ROC AUC and full ROC 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 20 of 28 
 AUC, sensi tivities, specificities, and paired differences, for benign and malignant masses. 
These analyses will be performed for IUS versu s Imagio (IUS+OA ) SG).      
For each endpoint, subgroup analyses will be performed in the same manner for those with a 
prior mam mogram as well as for those without a prior mammogram.  
1. Sensitivity, Specificity, Partial ROC AUC, Full ROC AUC, and Specificity for Fixed 
Sensitivity  
Individual reader specificity and sensitivity will be calculated from simple counts for the 2% 
POMs to con struct the respective ROC curves for IUS, the Imagio (IUS+OA).   
For sensitivity and specificity, GEE and ANOVA will be used to compute differences as well as 
to compute the two -sided 95% confidence intervals for the OA -IUS differences.    
The specificity advantage for fixed 98% sensitivity will be the primary endpoint ; a 10% 
absolute advantage for Imagio vs IUS in specificity for fixed 98% sensitivity is considered to be 
clinically relevant ; this drives the final sample size calculation .  The Hillis so ftware will be used 
to analyze the primary endpoint as well as for t he partial and full ROC AUCs .  The AUCs  will 
be computed from the respective ROC curves which are generated according to the POMs .  
Specificity and sensitivity are calculated using this fixed 2% cutoff.  Please be assured that the 
OR-DBM MRMC 2.51 (Hillis)  software does not pick or use a fixed cutoff.  In our application, 
the Hillis  software computes AUC, partial AUC, specificity gain at fixed sensitivity, and 
sensitivity gain at fixed specific ity using a full factorial ANOVA incorporating terms for readers , 
masses, and modalities.  The gain in specificity can be computed at a wide range of 
sensitivities.  The 98% sensitivity corresponds to a 2% false negative (FN) rate, but this 
unrelated to th e use of a fixed 2% POM cutoff for clinical decision making.      
The p artial AUC will be computed over  the 9 5-100% sensitivity range  using PROPROC .  To 
compute the specificity advantage for fixed sensitivity, interpolation may be required; a fixed 
sensitiv ity will be targeted, e.g., 98%.  To compute the specificity advantage and the partial 
area under the ROC, the specificities and sensitivities may need to be further computed from 
the ROC curves as needed.  The variances will be computed to construct the t wo-sided 95% 
CIs for Imagio (IUS+OA ), IUS, and for the respective pairwise Imagio  (IUS+OA)  - IUS 
difference.   
 2. NLR and PLR  
NLR and PLR will be analyzed using the logarithmic transformation and the delta method.    
Calculations will be performed using M ATLAB script: DLRATIOS.M. The method  of Nofuentes 
(14) will be used ; this reflects that the NLR and PLR are both ratios of independe nt random 
variables.    The DLRATIO S routine computes the standard deviation for the ratios of two 
independent random variabl es corresponding to the sensitivity and specificity which are both 
used to compute NLR and DLR.  
 
  GRAPHICAL INTERFACE FOR BI -RADS CATEGORY AND POM RATING  
For the purpose of this study, the readers will use a graphical interface to  assist them in  their 
asse ssment of applying their POM to the BI -RADS category for IUS and Imagio (IUS+OA ).    
The POM scale is linear for all BI -RADS categories; however, the scale for BI -RADS 3 is 
expanded ten -fold compared to other categories.  This design allows for a finer gra dation of 
the malignancy rating for BI -RADS 3 lesions, which in turn provides more data points for the 
ROC curve and enables a better estimation of the partial AUC.     One advantage of a 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 21 of 28 
 graphical metaphor is that it provides an aid to the Reader in assig ning first a POM score and  
then a BI-RADS category.  
 
 
 DATA COLLECTION AND QUALITY ASSURANCE  
12.1 Data Management  
Independent read data for this study is populated in Medidata Rave EDC System via direct 
data entry during read sessions from readers and read  monitor staff. Electronic data collection 
forms in Rave will be built during study start -up and designed to meet study aims and 
statistical analysis needs. Electronic  case report forms are created based on the study 
protocol, ACR -CRI scope of work stateme nt, contract, data flows, and data collection needs. 
The ACR -CRI Data Manager will ensure the eCRFs are tested appropriately, maintain proper 
version control and all i nternal and external/ sponsor stakeholders approve the content prior to 
finalization.  
Only authorized sponsor employees will have access to study data to the minimum necessary 
to fulfill a job role or function. User access will require individual log -in credentials, including 
user IDs and passwords.  
12.2 Quality Assurance  
12.2.1  Training  
Reader train ing will be provided as described in section 6.2 above.  
12.2.2  Quality Control  
Monitoring of the readers will be done by ACR in accordance with the procedures outlined 
under the Reader Study Process Work Flow Section of the protocol and the Independent 
Review Charte r. 
12.2.3  Monitoring  
Monitoring methods for assuring data quality for each reader, accurate qualification of each 
reader and reader responsibilities during the read process will be documented in the 
Independent Review Charter . 
 PARTICIPANT  RIGHTS AND CONFIDENTIALI TY  
13.1 Informed  Consent Forms  
Not applicable for this study.  
 
 Figure 3: Graphical input of BI -RADS category and POM rating  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 22 of 28 
 13.2 Participant  Confidentiality   
Reader sets will be de -identified to maintain PIONEER study participant’s confidentiality 
according to the Health Insurance Portability and Accountability A ct (HIPAA), any special data 
security requirements as stipulated by participating readers, and record retention per the 
sponsor’s requirements.   
Any data, forms, reports, video recordings, and other records that th e participating reader 
receives from the s ponsor will be identified only by a participant identification number 
(Participant ID , PID) from the PIONEER study to maintain  confidentiality. All records will be 
kept in a locked file cabinet. All computer entry and networking programs will be done using  
PIDs only. Information will not be released without written permission of the participant, except 
as necessary for monitoring by the FDA.  
13.3 Study Discontinuation  
The study may be discontinued at any time by th e sponsor for futility or by FDA, or other  
government agencies as part of their duties to ensure that research participants are protected.  
 PUBLICATION OF RESEARCH FINDINGS  
Any presentation, abstract, or manuscript will be made available for review by the s ponsor 
prior to submission.  
Study results may be published in support of reimbursement.   
Seno will review and approve all manuscripts .   
 REFERENCES  
 
    
1. Huang Z, Samuelson F, Tcheuko T, Chen W.  Adaptive Design in Multi -reader Multi -case 
Clinical Trials of Imaging Devices. Statistical Methods in Medical Research, 0(0) 1 -20   
2. Adaptiv e Designs for Clinical Trials. September 2018.   
3. Wittes J, Brittain E. The Role of Internal Pilot Studies in Increasin g the Efficiency of Clinical 
Trials. Statistics in Medicine, 9, 65 -72, 1990.  
4. Kieser, M., Friede, T. (2 003). Simple procedures for blinded sample size adjustment that 
do not affect the type I error rate.  Statistics in Medicine 22:3571 -3581.  
5. Friede T, Kiese r M. Sample Size Recalculation in Internal Pilot Study Designs: A Review. 
Biometrical Journal. 48, 4, 537-555, 2006.  
6. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses.  Biometrics. 
1994 Dec; 50 (4): 1029 -41. 
7. Dorfman, DD, Berbaum, KS, & Metz, CE (1992). Receiver operating characteristic rating 
analysis: Generalization to the populat ion of readers and patients with the jackknife 
method. Investigative Radiology, 27, 723 -731. 
8. Hillis, SL, Obuchowski, NA, Schartz, K M, & Berbaum, KS (2005). A comparison of the 
Dorfman -Berbaum -Metz and Obuchowski -Rockette methods for receiver operating 
characteristic (ROC) data. Statistics in Medicine, 24, 1579 -1607 DOI:10.1002/sim.2024.  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 23 of 28 
 9. Hillis, SL (2007). A comparison of denominator d egrees of freedom for multiple observer 
ROC analysis.  Statistics in Medicine, 26:596 -619 DOI:10.1002/sim.2532.  
10. Hillis, SL, B erbaum, KS, & Metz, CE (2008). Recent developments in the Dorfman -
Berbaum -Metz procedure for multi -reader ROC study analysis. Acade mic Radiology, 15, 
647-661. DOI:10.1016/j.acra.2007.12.015.  
11. Hillis, SL, Obuchowski NA, Berbaum, KS (2011). Power estimation for multi -reader ROC 
methods. Academic Radiology, 18, 129 -142. DOI:10.1016/j.acra.2010.09.007.  
12. Hillis, SL. (2014). A marginal mean  ANOVA approach for analyzing multi -reader multi -case 
radiological imaging data. Statistics in Medicine, 33, 330 -360. DOI:10. 1002/sim.5926.  
13. Obuchowski, NA, Rockette, HE (1995). Hypothesis testing of diagnostic accuracy for 
multiple readers and multiple tests: An ANOVA approach with dependent observations. 
Communications in Statistics -Simulation and Computation, 24, 285 -308. 
14. Nofuentes JA, de Dios Luna del Castillo J (2007).  Comparison of the likelihood ratios of 
two binary diagnostic tests in pa ired designs.  Statistics in Medicine 2007 Mar. 26, 4179 -
4201.  
 
 
 VERSION HISTORY  
Version  Date  Description of Changes  
1 04Mar19  Original  protocol  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 24 of 28 
 Version  Date  Description of Changes  
2 03Jul 19  • General  
˃ Multiple formatting changes and corrections to typographical errors were 
made throughout the document  for clarification  
˃ Minor additions of text for clarification throughout the document  
˃ “Imagio (OA + IUS + Senogram)” or “ Imagi o (OA + IUS ) Post -Senogram”, 
changed to Imagio (IUS +OA) throughout the document   
• Page 1 – Clinical Study Protocol Title Page: Indication statement  
reworded for clarity  
• Page 2 Tom Stavros title Changed to Chief Medical Officer  
• Page 6 – List of Abbreviatio ns and Definitions of Terms: added 
abbreviations and terms used throughout the protocol  
• Section 4 – Senogram: entire section re vised to clarify the Senogram 
status post the Reader -01 Feasibility Study  
• Section 5 – Study Design: text revised and or added to clarify reader 
training  
• Section 6.2, item 2 Interactive reading, c: deleted “Some malignant 
masses that could cause false negat ive Reader -02 Pivotal Study OA 
reads.”  
• Section 6.2, item 4 Pass/Fail criteria: revised text to clarify pass / fail.  
• Section 7.2 E xclusion Criteria: deleted “Masses used for development, 
tuning and training the Senogram.  
• Section 8.1 : revised Figure to refle ct Reader -02 Pivotal Study workflow  
• Section 8.5: deleted “ When possible, the independent QARs will circle 
the mass of interest f or IUS and OA on available  mammograms. ” 
• Section 10.1: deleted “This Pivotal Study will further evaluate the primary 
and secondary endpoints for the benign and malignant subsets with Bi -
Rads >0 mammography data. The retrospective powers will be calculated 
to check if there are sufficient numbers of benign and malignant image 
sets to reach statistically significant conclusion s.” 
• Section 10.7, item 2 Upgrades / Downgrades: deleted entire item  
• References: deleted reference 8  + 9 and added Chen as 8  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 25 of 28 
 3 23 Sep 
2019 • General  
˃ Minor additions of text throughout document for clarification  
• Page 5 - List of Abbreviations and Definitions of Terms: added : CB 
abbreviation and HIPPA  
• Section 2.1 – Added :  A clinically significant gain “of 10% ” 
• Section 2.2 - Revised the order of Secondary Endpoints: NLR, PLR, 
Partial AUC and deleted the endpoint:  Observed and model -adjusted 
specificities, sensitivities, and paired differences.  
• Section 5  - Removed “representing current clinical practice” ;  – Added : 
(360-10 co lor balance masses =350); Added language at end of section 
clarifying the handling of color balance masses included in pivotal study  
• Section 7.3  - Added clarification “per block to be the same for all readers”  
• Section 8.1  - Added sentences  “ The order of masses per block wi ll be 
the same for each participating reader.” “Each reader will be separately 
proctored by read monitors  to ensure that no technical issues arise and 
that reader scoring is independent.”  
• Section 8.2 - Added sentence “Readers read block s including IUS and  
Imagio (IUS+OA) reads in sequential order in accordance to their 
schedule and read speed .” 
•  Section 8.4 - Clarified sentence. “BBRF will generate the randomly 
selected read list.  The read order will be the same for all readers within 
each block of 120 ma sses presented .” 
• Section 10  -  Added “(360 -10 color balance masses=350); Text added on 
color balance mass  exclusion.  
• Section 10.2 - Text added to add color balance exclusion and added: 
“Neither futility nor efficacy will be assessed; this is not an adaptiv e 
design.”  
• Section 10.4 - Text added to clarify color balance and recommendations 
for interim analysis added.  
• Clarification that “No alpha will be spent to perform this interim analysis 
since this analysis is for sample siz e re-estimation”  
• Section 10.7  added - Hierarchal Testing  section  
• Section 10.8 – Added:  
All analyses will be performed in a GCP -controlled environment using the 
Hillis software (see references 3 -7)”; Clarification of color balance masses; 
Clarified “a 10% absolute advantage for Imagio vs  IUS in specificity for fixed 
98% sensitivity is considered to be clinically relevant; this drives the final 
sample size calculation.”  
“The partial AUC will be computed over the 95 -100% sensitivity range . 
Removed “.005” lang uage.  
Deleted previous wording o n NLR/PLR and added: “NLR and PLR will be 
analyzed using the logarithmic transformation and the delta method.    
Calculations will be performed using MATLAB script: DLRATIOS.M. The 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 26 of 28 
 Version  Date  Description of Changes  
changes in NLR and PLR correspond to the 10 % specificity gain for the 
prima ry endpoint.”  
References:  Added Keiser and deleted Chen  
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 27 of 28 
 4 4Nov2019  • General  
˃ Multiple formatting changes and corrections to typographical errors 
were made throughout the document for clarification  
• List of Abbreviations and Definitions of Terms: added abbre viations and 
terms used throughout the protocol  
• Section 10.2: Reader/Image Set Sample Size : Added  the s upporting 
calculations including the software output  and added  “in increments of 
120 masses p er block ” to clarify block description and  clarified “All 
original color balance masses will be will be replaced with comparable 
masses and image sets within the final analysis from the PIONEER 
Pivotal overage masses.  
• Section 10.2: Reader/Image Set Sample Si ze: Removed “and from the 
PIONEER Pilot Study  as needed .” 
• Section 10.3 Additional Hypothesis Tests added  describing hypothesis 
tests to be done on s econdary endpoint s:  NLP, PLR, Partial ROC/AUC   
• Section 10.5 , 10.5.1 and 10.5.2 Interim Analysis added language to 
clarify the  Plan (10.5.1) and the Methodology (10 .5.2)  to be used with the  
interim analysis  
• Section 10.5.3: Timing:  Number of masses added to clarify blocks  
• Section 10.5.4: Execution:  Language clarified “ The unblinded  
biostatistician wi ll only evaluate the overall SD which was the nuisance 
parameter  driving sample size for the fixed 10% difference  to be 
detected.  The unblinded biostatistician will not need to take the observed 
delta into account.  Other than the preplanned sample size calculation to 
determine the remaining blocks required to complet e the study, no other 
information will be reveale d to the Sponsor or to any other members of 
the analysis team.  The IA will be executed to the blinded principle .”    
•  Section 10.9: Data Analys es:  Sentence removed  the sentence : “In 
clinical practice the  Probability of Malignancy (POM)  Scores (0 100) ar e 
standardized such that a BI -RADS 3 (probably benign) shows a likelihood 
of cancer to be >0% up to 2% inclusive.”  
• Section 10.9: Data Analyses: Added the sentence under 1: “Specificity 
and sensitivity are ca lculated using this fixed 2% cutoff.  Please be 
assured that the OR -DBM MRMC 2.51 (Hillis) software does not pick or 
use a fixed cutoff.  In our application, the Hillis  software computes AUC, 
partial AUC, specificity gain at fixed sensitivity, and sensitiv ity gain at 
fixed specificity using a full factorial ANOVA incorporating terms for 
readers, masses, and modalities.  The gain in specificity can be 
computed at a wide range of sensitivities.  The 98% sensitivity 
corresponds to a 2% false negative (FN) rate , but this unrelated to the 
use of a f ixed 2% POM cutoff for clinical decision making .”    
• Section 10.9: Data Analyses: Added the sentence under 2:“ The method 
of Nofuentes (14) will be used; this reflects that the NLR and PLR are 
both ratios of independent  random variables.   The DLRATIOS rout ine 
computes the standard deviation for the ratios of two independent 
random variables corresponding to the sensitivity and specificity which 
 
Imagio Reader -02 Study Protocol  Confidential  
November 4 , 2019  – Version 4.0 Page 28 of 28 
 Version  Date  Description of Changes  
are both used to compute NLR and DLR. ” 
• References :  Added:   
Huang Z, Samuel son F, Tcheuko T, Chen W.  Adaptive Design in 
Multi -reader Multi -case Clinical Trials of Imaging Devices. Statistical 
Methods in Medical Research, 0(0) 1 -20   
Adaptive Designs for Clinical Trials. September 2018.  
Wittes J, Brittain E. The Role of Internal  Pilot Studies in Increasing 
the Efficiency of Clinical Trials. Statistics in Medicine, 9, 65 -72, 1990.  
Friede T, Kieser M. Sample Size Recalculation in Internal Pilot Study 
Designs: A Review. Biometrical Journal. 48, 4, 537 -555, 2006.  
Bauer P , Kohne K. Ev aluation of experiments with adaptive interim 
analyses.  Biometrics. 1994 Dec; 50 (4): 1029 -41. 
Nofuentes JA, de Dios Luna del Castillo J (2007).  Comparison of the 
likelihood ratios of two binary diagnostic tests in paired designs.  
Statistics in Medicine  2007 Mar. 26, 4179 -4201.  
 
 
Statistical Analysis Plan 
04 November 2019 V5  
Page 1 of 32   READER STUDY -02 
Statistical Analysis Plan  
Imagio Pivotal Multi -Reader, Multi -Case Study of Optoacoustic 
Images versus Imagio Ultrasound to Guide Decision to Biopsy  
Philip Lavin PhD, FASA,  FRAPS 
Roger Aitchison , ScM  
For 
Seno Medical Instruments 
8023 Vantage Dr, Suite 1000 
San Antonio, TX 78230  
CONFIDENTIALITY STATEMENT  
This document contains information that is the property of Seno Medical Instruments Inc. and 
therefore is provided to you in confidence for review by you,  your staff, an applicable 
Institutional Review Board and regulatory authorities. It is understood that this information will 
not be disclosed to others without written approval from Seno Medical Instruments Inc., except 
to the extent necessary to obtain i nformed consent from those women undergoing evaluation 
with the Imagio™ system.  
Statistical Analysis Plan 
04 November 2019 V5  
Page 2 of 32 Table of Contents  
1.ACRONYMS ................................ ................................ ................................ .............................  5 
2.STATISTICAL  METHODS  PLANNED  IN THE  PROTOCOL  AND DETERMINATION OF
SAMPLE  SIZE  ................................ ................................ ................................ ..........................  6 
2.1. Statistical and Analytical  Plans  ................................ ................................ ................................ . 6 
2.1.1.  Definitions and General Considerations for Data  Analysis  ................................ ...............  6 
2.1.2.  Classification of Cancer  Status  ................................ ................................ ..........................  8 
2.1.3.  Analysis  Populations  ................................ ................................ ................................ ..........  8 
2.1.4.  Sample Size Calculations  ................................ ................................ ................................ ... 9 
2.1.5.  Disposition of Masses  ................................ ................................ ................................ ...... 11 
2.1.6.  Demographic and Other Baseline  Characteristics  ................................ ............................  11 
2.1.7.  Medical History and Concomitant Medications  ................................ ...............................  11 
2.1.8.  Effectiveness Methodology  ................................ ................................ ..............................  11 
2.1.9.  Effectiveness  Analysis  ................................ ................................ ................................ ..... 13 
2.1.10.  Hypotheses to be Tested  ................................ ................................ ................................ ... 15 
2.1.11.  Data Analysis Methodology Data  Analyses  ................................ ................................ ..... 16 
2.1.11.1. Adjustments for  Covariates  ................................ ................................ ..........................  17 
2.1.11.2. Handling of Dropouts or Missing  Data  ................................ ................................ ........  17 
2.1.11.3. Interim Analyses and Data  Monitoring  ................................ ................................ ........  17 
Execution  ................................ ................................ ................................ ................................ . 19 
2.1.11.4. Multiple Comparisons /  Multiplicity  ................................ ................................ ............  19 
2.1.11.5. Examination of  Subgroups  ................................ ................................ ...........................  19 
2.1.12 Evaluating the  SenoGram  ................................ ................................ ................................ .... 19 
2.1.13. Safety  Evaluation  ................................ ................................ ................................ ................  19 
2.1.13.1. Extent of  Exposure  ................................ ................................ ................................ ...........  19 
2.1.13.2. Adverse  Events  ................................ ................................ ................................ .................  19 
2.1.13.3. Clinical Laboratory  Evaluation  ................................ ................................ .......................  19 
2.2. Hypotheses to be  Tested  ................................ ................................ ................................ ..........  20 
2.3. Determination of Sample  Size ................................ ................................ ................................ . 20 
3.CHANGES  IN THE  CONDUCT  OF THE  STUDY  OR PLANNED ANALYSES  ................  20 
4.REFERENCES:  ................................ ................................ ................................ .......................  20 
Statistical Analysis Plan 
04 November 2019 V5  
Page 3 of 32 APPENDIX 1:  OR USER MANUAL SECTION 9  ................................ ................................ ...... 21 
APPENDIX 2:  SAMPLE OUTPUT FOR SPECIFICITY ADVANTAGE  ................................ .. 21 
SUMMARY OF CHANGES:  ................................ ................................ ................................ .........  21 
Statistical Analysis Plan 
04 November 2019 V5  
Page 4 of 32 1. ACRONYMS
ACR  American College of Radiology  
AE Adverse Event  
ANOVA  Analysis of Variance  
AUC  Area Under the Curve  
BBRF  Boston Biostatistics Research Foundation 
BI-RADS (BR)  Breast Imaging -Reporting and Data System  
CB Color Balancing  
CDU  Conventional Diagnostic Ultrasound  
CI Confidence Interval  
CSR  Clinical Study Report  
EDC  Electronic Data Capture System  
FDA  Food and Drug Administration  
GCP  Good Clinical Practice  
GEE  Generalized Estimating Equations  
IA Interim Analysis  
ICF Informed Consent Form  
ICH International Conference on Harmonization  
IRB Institutional Review Board  
ITD Intention -to Diagnose  
IUS Imagio Internal Ultrasound  
MRMC  Multi -reader, Multi -case 
Statistical Analysis Plan 
04 November 2019 V5  
Page 5 of 32 NLR  Negative Likelihood Ratio  
OA Opto -acoustics  
OR Obuchowski -Rockette  
PD Protocol Deviation  
PLR Positive Likelihood Ratio  
POM  Probability of Malignancy  
PMA  Pre Market Approval  
ROC  Receiver Operating  Characteristic  Curve  
SAP Statistical Analysis Plan  
SAS Statistical Analysis System  
SG SenoGram  
SSRE  Sample Size Re -Estimation  
TPB Truth Panel Benign  
2. STATISTICAL  METHODS  PLANNED  IN THE  PROTOCOL  AND
DETERMINATION OF SAMPLE  SIZE
The objective of this analysis plan is to describe the planned full study analysis.  
2.1. Statistical and Analytical  Plans  
2.1.1.  Definitions and General Considerations for Data  Analysis  
1.All calculations, unless otherwise specified, will be performed in a GCP - 
complian t environment using SAS statistical software  (version 9. 3 or
later), StatXact  (version 10 or later ), or OR -DBM MRMC ( version 2.5 or
later).
2.This Statistical Analysis Plan (SAP) is based on Clinical Trial Protocol
entitled: Imagio Pivotal Multi -Reader, Mult i-Case (MRMC) Study of
Optoacoustic Images versus Imagio Ultrasound to Guide Decision to Biopsy .
3.This study is a single arm, controlled, blinded,  MRMC study using a sequential
design.
4.This pivotal study will be registered at  clinicaltrials.gov
5.There will be up to 20 new, independent, prospectively qualified readers to
evaluate images using standardized equipment at American College of Radiology
Statistical Analysis Plan 
04 November 2019 V5  
Page 6 of 32 (ACR). These readers will not have previously served as Seno readers for the 
PIONEER Pivotal or Pilot Study (henceforth referred to as the PIONEER Study) , 
MAESTRO Study, or READER -01 Feasibility  Study.  
6.All readers will read in accordance with Section 5 of the protocol. Each
complete image set is based on a single mass per PIONEER Pivotal Study
subject.
7.The image sets  for this study will come from the PIONEER Pivotal Study.  Image
sets are constructed from existing mass -specific images (mammography plus
ultrasound and opto -acoustics,  alone and in combination).  Image set s will be
allocated for reader training , testing, and image set reads. Image sets previously
used for reader testing or training will remain for testing  and training .  Image sets
used for the READER -02 pivotal study  were not  previously used for reader
testing  or training . No READER -02 study image sets will be used for SenoGram
(SG)  or Color Balance algorithm training . It is estimated that at least 840 image
sets will be available for reads and remaining (~ 900) image  sets will be available
for SG training.
8.A total of 480 to 840 complete image s ets from the original PIONEER Pivotal
Study Intention -to Diagnose (ITD) population will be randomly selected from
within  the PIONEER  Pivotal Study.
•A prospective sampling plan dated February 26, 2019 has been finalized
and implemented to select the targeted proportion with and without
mammograms for benign masses. [Note: mammograms were present
for nearly all malignant  masses  which reflects real world practice .]
•Image sets will be organized in blocks of 120 per block with each block
containing 75 ben ign (including three high risk masses defined as
atypical ductal hyperplasia, atypical lobular neoplasia, and lobular carcinoma
in situ ) and 45 malignant masses classified by Conventional Diagnostic
Ultrasound (CDU) as BI -RADS (BR) 3 to 5 selected at rando m in
proportion to the original distribution of  BI-RADS classifications
among subjects in the PIONEER  Study.
•A reserve of up to 60 different overage masses from the PIONEER
Pivotal Study will be available for back -up utilization in the event
that any masse s in the sampling plan cannot be utilized  in accordance
with the imaging core lab quality assurance process .
•The prospective sampling plan is solely based on the PIONEER
Pivotal Study while reserve  cases may also be drawn from the
PIONEER Pilot Study  if a suitable PIONEER Pivotal Study  overage
mass match cannot be found .
9.Color balance ( CB) masses (n=29) used to tune the Color Balance Algorithm will
be replaced for the  final analyses .
10.Within the Imagio (IUS +OA) test arm of the study , each study reader will view
the SenoGram (SG) following the scoring  of the IUS and OA feature scores after
viewing the Imagio ( IUS+OA ) images.  The POM and BI -RADS data collected
after the SG viewing will be referred to as Imagio ( IUS+OA ) in the remainder of
this document.  The initial IUS read without feature scoring will  serve as the
Statistical Analysis Plan 
04 November 2019 V5  
Page 7 of 32 internal control, best representing current clinical practice. 
11.The primary endpoint is to evaluate the gain in specificity  at fixed 98% sensitivity
for Imagio ( IUS+OA ) vs IUS according to a formal hypothesis test to detect a
10% absolute  advantage  with 80% power .  The differences that can be detected
with 80% power will also be computed for the secondary  endpoint (partial AUC
[pAUC ]).
12.The sample size calculations conservatively assume that both readers and masses
are random effects. The sample size was computed using the following statistical
software written by Stephen Hillis and entitled: Multi -Reader Sample Size
Program for Diagnostic Studies  [http://perception.radiology.uiowa.edu.] .
13.For 80% power, a two -sided hypothesis test with a two -sided 5% alpha and 15
readers, a sample size of 854 image sets is neede d; the 79% power with 840
image sets is deemed adequate to test the primary hypothesis test; the sample size
was calculated using the same intra - and inter -reader standard deviation observed
in the READER -01 Feasibility  Study.
14.A blinded interim analysis is  planned after all readers complete the reading of the
first three blocks (360 -10 Color Balance = 350 image sets). The interim analysis
will only assess the  reader  variability associated with the primary endpoint; the
sample size may be left at 480 image sets or increased up to 840 image sets
based solely on the variability determined from the primary analysis.
15.READER -01 Feasibility Study data will not be combined with the READER -
02 Pivotal Study data but may be referenced in the final P re-market Approval
(PMA).
16.Effectiveness analyses (interim and final) will be performed without the CB cases as the
primary analysis.   The interim analysis will be based on 350 masses without replacement
while the final analysis will be based on the sample size to be  determined to potentially
include all or some of the 29 replacement cases.
17.For completeness, a pre-defined subset of the PIONEER Study tables and
listings will be regenerated for the subset of 480 to 840 masses using the
READER -02 Pivotal Study data.
18.For completeness, the differences which can be detected with 80% power  will
be calculat ed for the primary endpoint (specificity gain at 98% sensitivity ) and
for the secondary endpoint (pAUC over 95-100%  sensitivity ).
19.A hierarchical testing strategy will be implemented to extend labeling by
testing effectiveness in the following order : gain in specificity for fixed 98%
sensitivity , decrease  in NLR, gain in  PLR, and gain in pAUC over 95% to
100% sensitivity  where gain is the difference between the OA/U S and IUS
values.
2.1.2.  Classification of Cancer  Status  
Study masses will be classified as biopsy -confirmed cancer, biopsy -confirmed benign or 
Truth Panel benign from the PIONEER  Study .  Biopsy -confirmed high -risk masses will 
be included and will be classified as benign for purposes of effectiveness calculation s. 
2.1.3.  Analysis  Populations  
Statistical Analysis Plan 
04 November 2019 V5  
Page 8 of 32 Safety results for the safety population will be reported for the final masses read as was 
done for the PIONEER Pivotal Study.  
Masses will be selected according to the Mass Sampling Plan.  BBRF stratified by diagnosis, 
original site  CDU BI -RADS, and whether the mammogram images were available in select ing the 
masses at random from the universe of qualified masses analyzed in the PIONEER Pivotal Study. 
The Sampling Plan depends solely upon clinical study and statistical criteria, incl uding input from 
the FDA.  SenoGram performance was not considered and had no impact on the plan, nor was the 
SenoGram development group involved.  The masses to be sampled excluded masses used in the 
READER -01 study as well as masses used for training and  testing readers.  The sampling strategy 
reflected  the overall benign mass (including high risk masses) and malignant mass distribution  in 
the PIONEER Pivotal Study .  When subjects had multiple masses, only the first mass was 
considered.  Blocks of 120 masses were constructed to include 75 benign masses (including 3 
high risk mases) plus 45 cancer masses according to the  stratifi cation noted above.    
At the interim timepoint and after study completion, all protocol deviations (PD) will be reviewed. 
Technica l protocol deviations (such as a system error which would not allow the SenoGram to be 
viewed or a technical issue that will not allow an image to be viewed by a reader ) will be handled 
during a Protocol Deviation Meeting prior to the interim and final ana lysis; if an image display 
issue occurs, then that case will  be re -presented to a reader once the technical issue is corrected.  If 
the SenoGram would not display to a reader, that case would be excluded from the analysis. 
Finally, readers not completing a ll reads (i.e . due to illness or family emergency) for non -study 
related reasons will be replaced by one of the pre -determined five back -up readers as necessary. 
Seno will not have access to any data from readers that did not complete all reads.  No reader  will 
be excluded as an outlier.  
2.1.4.  Sample Size Calculations  
The sample size will be based on the primary effectiveness endpoint, namely the gain in 
specificity for fixed 98% sensitivity.  This calculation depends upon the number of image sets 
(one per mass) to be read, the number of readers, as well as the inter -reader variability associated 
with the underlying models used for analysis.  
The test of the primary hypothesis is powered to detect a 10% absolute specificity advantage 
(superiority) as the alte rnative hypothesis with no specificity advantage as the null hypothesis.  
The primary endpoint will be evaluated in the following testable hypotheses:  
H0:  S Imagio  = S IUS 
H1:  S Imagio  ≠ S IUS 
where S Imagio  and S IUS   represent specificity,  values associate d with Imagio (IUS + OA) and IUS.  
The sample size calculations conservatively assume that both readers and masses are random 
effects; an ANOVA model will be used to compute sample size.  The sample size was computed 
using the following statistical software  written by Stephen Hillis and entitled: Multi -Reader 
Sample Size Program for Diagnostic Studies [http://perception.radiology.uiowa.edu.].   
Statistical Analysis Plan 
04 November 2019 V5  
Page 9 of 32 For 80% power, a two -sided hypothesis test with a two -sided 5% alpha, and 15 readers, a sample 
size of 854 image se ts is needed to detect a 10% absolute advantage in specificity for Imagio (IUS 
+ OA) vs IUS, assuming a fixed 98% sensitivity and the same intra - and inter -reader standard
deviation observed in the Reader -1 Feasibility Study.
The supporting calculations i ncluding the software output follow:  
Initially, 360 masses will be read by all readers for the purposes of performing the interim analysis 
to assess the sources of variation and to rerun the sample size estimate for the primary 
effectiveness endpoint.  N either futility nor efficacy will be assessed; this is not an adaptive 
design.  
The sample size may be increased from the minimum of 480 image sets to a maximum of 840 
image sets (7 complete blocks) in increments of 120 masses per block.  All masses used in the 
color balance algorithm  will be excluded from the final analysis; these masses will be replaced 
from the PIONEER Pivotal overage masses and the PIONEER Pilot Study as needed.  
The maximum sample size to be used for the study will be capped at 84 0 masses.   An overage 
mass set will be set aside in case quality control issues are found with the images and replacement 
masses are needed.  After excluding the pool of 840 masses and overage masses, approximately 

Statistical Analysis Plan 
04 November 2019 V5  
Page 10 of 32 900 masses will remain for independent S enoGram training.  No masses used to train the 
SenoGram, will be in the pool of 840 study masses plus overage.    We have removed the 29 
masses from the pool of study masses which were mistakenly included from the original color 
balance algorithm.  
Every eff ort will be made to identify missing reader generated data in real time.  Each block of 
120 masses will include 75 benign (72 benign + 3 high risk) and 45 malignant masses to represent 
the PIONEER study.  
With the exception of masses excluded due to protoc ol deviations, all complete reads will be 
included in all analyses, consistent with an “Intention -to-Diagnose” approach.  
2.1.5.  Disposition of Masses  
A total of 840 masses with 120 masses per block have been selected from the PIONEER 
Pivotal Study ITD population . The additional 60 overage masses allowed for 
replacement of any mass that might prove unreadable. Replacement of any masses will 
be documented in the Clinical Study Report (CSR).  
2.1.6.  Demographic and Other Baseline  Characteristics  
Clinical presentation and medical history (limited to the specific masses used from the 
PIONEER database), including the referral indication, palpability of mass, breast density, 
age, menopausal status, presence of breast implants, number of masses (in PIONEER), 
and mammographic intent will be summarized using descriptive statistics.  
Summary tables will display demographic and baseline characteristics by diagnostic 
status (benign+TPB, cancer ); TBP were the masses without biopsy which were 
declared to be Truth Panel Benign ; high risk masses will be included with the 
benign masses.  
2.1.7.  Medical History and Concomitant Medications  
Detailed medical history (as presented to the readers) will be listed. Concomitant 
medications are irrelevant to this study.  
2.1.8.  Effectiveness Methodo logy 
The following approaches (Hillis OR -DBM MRMC 2.51) were used to treat readers as correlated 
and as random effects in analyses .  See Appendix  1 for OR User Manual Section 9 for the 
underlying models and corresponding variance component and degree of freedom equations 
including notations.   
Analyses for three  study designs are presented  in Appendix 2 from the READER -01 analyses for 
the following scenarios with primary focus on th e standard modality -by-reader -mass factorial 
study design, where each reader reads all masses  for both diagnostic tests.  See Attachment 1 for 
discussion on using GEE to estimate specificity in SAS using READER -01 data.   
Analysis 1 treats both as random,  and thus results generalize to both the population of readers and 
cases – this is the situation for which the DBM and Obuchowski -Rockette (OR) procedures were 
originally designed. However, within the OR/DBM analysis framework one can also analyze the 
Statistical Analysis Plan 
04 November 2019 V5  
Page 11 of 32 data treating only cases as random (Analysis 2) or readers as random (Analysis 3), although we 
note that these analyses are not unique to OR/DBM. Analyses 2 and 3 are viewed as supportive 
analyses  while Analysis 1 is viewed as the primary analysis approach . 
For all three analyses, the null hypothesis of equal treatments is tested in part (a), diagnostic test  
difference 95% confidence intervals are given in part (b), and individual diagnostic test two-sided 
95% confidence intervals are given in part (c)  of the output. For the DBM procedure, parts (a) and 
(b) are based on the diagnostic test x reader x mass ANOVA of jackknife pseudo -values while
part (c) is based on the reader x case ANOVA of jackknife pseudo -values for the specified
diagnostic test . For the OR procedure, parts (a) and (b) are based on the diagnostic test  x reader
ANOVA of reader -performance outcomes (e.g., AUCs) while part (c) is based on the reader
ANOVA of reader -performance outcomes for the specified diagnostic test. These ANOVA tables
are displayed in Appendix 2 .
Different denominator “error terms” (these are the denominators used for the F statistics) are used 
as indicated for parts (a), (b), and (c) according to whether reader and case are treated as fixed or 
random factors, and their formulas are provided in the output. Note that the diagnostic test  
confidence intervals in part  (c) are based only on the data for the specified diagnostic test, rather 
than the pooled data. Diagnostic test difference  95% confidence intervals for each read er are 
presented in part (d) of Analysis 2: for DBM each interval is  based on the diagnostic test  x mass 
ANOVA table for the specified reader; for OR each interval is based on the  OR variance and 
Cov1 estimates computed separately for each reader.  
Analys is 1 
Our planned analysis ( Analysis 1 ) treats both readers and masses as random samples. Results 
apply to the reader and mass populations — this is the situation for which DBM and OR were 
initially created.   
Analysis 2 
Analysis 2 treats only masses  as a random sample .  Results apply to the population of masses but 
only for the readers used in the study. For this analysis, inferences are based on the  estimated error 
covariance matrix, treating readers as fixed. These two methods will give almost the same results 
for typical studies where the total number of cases is at least moderate (≥ 50). Diagnostic test 
difference s and two -sided  95% confidence intervals are presented for each reader in part (d).  
Analysis 3  
Analysis 3 treats only readers as a random sample. Results apply to the population of readers but 
only for the masses used in this study. These results are based on a conventional diagnostic test x 
reader ANOVA  for the AUCs (or other measure s), where reader is a ra ndom factor and diagnostic 
test is a fixed factor  which is include d for completeness. This is the same as a repeated measures 
ANOVA where diagnostic test  is the repeated measures factor, i.e., readers provide an outcome 
(e.g., AUC) for each diagnostic test .  For two te sts, this analysis is equivalent  to a paired t test 
performed on the reader -specific AUC estimates. DBM and OR give the same results here, and it 
Statistical Analysis Plan 
04 November 2019 V5  
Page 12 of 32 does not matter with error covariance method is used with OR because the covariance does  not 
enter into the F statistic.  
See the respective equations for variance components and degrees of freedom (DF)  in Appendix 
1. 
2.1.9.  Effectiveness  Analysis  
There is a formal  test of hypotheses for the primary endpoint. Other p -values that are 
generated for other endpoints will be regarded as descriptive statistics. Imagio 
(IUS+OA ) represents  the reader input after viewing the Imagio ( IUS+OA ) images and 
SenoGram results. IUS r epresents the reader input prior to any IUS feature scoring , but 
after reader training on Imagio (IUS+OA).   
The following will be used to assess the pivotal study.  
Table 1: Effectiveness Analysis for Study Endpoints  
Endpoints by Cohort  Analysis/Software  
Primary  
Gain in specificity Imagio ( IUS+OA ) vs. 
IUS at fixed 98% sensitivity interpolated 
from the ROC AUC curves using methods 
of Obuchowski -Rockette (OR).   Effect 
estimates ( two-sided 95% CIs) will be 
derived using OR -DBM MRMC methods.  
The interim analysis to re -assess pivotal 
study sample size will be determined using 
OR-DBM  MRMC sample size program.  OR-DBM MRMC  
Sample Size: OR -DBM -MRMC Power 
program, nQuery  v7, SAS (PROC 
POWER), and/or PASS v15.0.5.  
Statistical Analysis Plan 
04 November 2019 V5  
Page 13 of 32 Secondary  
Partial AUC: Difference ( Imagio 
(IUS+OA ) vs. IUS) in partial Receiver 
Operator Characteristic (ROC) Area Under 
the Curve (AUC) for 95-100% sensitivities 
using the OR methods.  OR-DBM 
Specificity and Sensitivity:  Specificity is 
defined using the percent with a negative 
result (POM <2%) among all 
benign+TPB masses (to include all high-
risk masses ).  Sensitivity is defined using 
the percent with a positive result (POM 
>2%) among all malignant masses.
Observed and model -adjusted specificity 
and sensitivity will be reported for  
Imagio ( IUS+OA ) vs. IUS using a 2% 
Probability of Malignancy (POM) cutoff.  
These analyses will be repeated for POM 
cutoffs of 1%, 3%, 4%, 5%, 6%, and 7%.  
High risk masses will be included in the 
calculations for specificity.  SAS PROC GEE and MIXED treating 
masses as independent observations and 
readers as correlated and then  readers as 
independent and masses as correlated.  
Two-sided 95% confidence intervals (CIs) 
for sensitivity a nd specificity will be 
computed for IUS, for Imagio ( IUS+OA ), 
and for the pairwise difference.  
Confidence intervals will be constructed 
treating masses as independent 
observations with readers as correlated 
and then  readers as independent with 
masses corr elated . 
Negative Likelihood Ratios (NLR) and 
Positive Likelihood Ratio (PLR) for IUS 
and Imagio ( IUS+OA ), NLR defined as 
((1- observed sensitivity)/observed 
specificity), and relative NLR and PLR for 
paired designs.  SAS: Univariate 95% CI for PLR and NLR 
with variances fit using the logarithmic 
transformation and the delta method, 
reference PIONEER Table 14.2.3.2.  
MATLAB  script: DLRATIOS.M  
Statistical Analysis Plan 
04 November 2019 V5  
Page 14 of 32 SenoGram performance using the 
following metrics from the study 
endpoints:  
a)Sensitivity and specificity for
SenoGram classification based on
predicted probability and the
SenoGram threshold, with  subgroup
analysis for masses with and
without mammogram BI -RADS
data.
b)Specificity at fixed sensitivity
(98%) for SenoGram classification
as in (a).
c)Partial AUC (over 9 5% to 100%
sensitivity , inclusive) for
SenoGram classification as in  (a).For each metric, a summary table for each 
reader (where appropriate) and for all 
readers to contain the following:  
•Measured value using  READER -02
feature  data.
•Estimated value from  SenoGram
cross -validation with PIONEER
feature  data.
•Estimated value from  SenoGram
predictions for masses with
PIONEER  data.
Exploratory  
OA Feature Score Distributions:  
•Benign vs. malignant  masses
•Benign masses only – mammogram
vs no  mammogram
POM Score Distributions:  
•Benign vs. malignant  masses
•Benign masses only – mammogram
vs no  mammogram
Inter -reader variability assessment s (POM  
and feature scoring):  
•Mammogram
•IUS
•OA.Summary Statistics by reader. Average over 
readers and then summarize means for 
overall. Use a Wilcoxon Rank Sum  test. 
Reference PIONEER T14.2.10.1 
[t_14_02_1x_feat -10-_01] 
Reference PIONEER Table 14.2.9.1 
[t_14_02_09_pom -01] 
Statistics  will be calculated  to 
assess inter -reader variabilities. 
2.1.10.  Hypotheses to be Tested  
The test of the primary hypothesis is powered to detect a 10% absolute specificity advantage 
(superiority) as the alternative hypothesis with no specificity advantage as the null hypothesis.  The 
primary endpoint will be evaluated in the following testable  hypotheses:  
H0:  S Imagio  = S IUS 
H1:  S Imagio  ≠ S IUS representing a 10% absolute increase  
Statistical Analysis Plan 
04 November 2019 V5  
Page 15 of 32 where S Imagio  and S IUS   represent specificity,  values associated with Imagio (IUS + OA) and IUS.  
The following hypothesis tests will be applied using the observed estimates for the following  
secondary endpoints:  
•NLR:
oH0: NLR IUS = NLR Imagio  vs
oHA: NLR IUS ≠ NLR Imagio representing a reduction
•PLR:
oH0: PLR IUS = PLR Imagio  vs
oHA: PLR IUS ≠ PLR Imagio representing a n increase
•Partial ROC AUC:
oH0: pAUC IUS = pAUC Imagio  vs
oHA: pAUC IUS ≠ pAUC Imagio representing a n increase
Hierarchical testing will be applied to seek labeling claims if warranted by the pre -defined  
testing procedure (see Section 2.1. 11.4). 
2.1.11.  Data Analysis Methodology 
Data  Analyses  
As for the PIONEER Pivotal Study, analyses will be based on independent readers for POM, BI - 
RADS and feature scores (IUS, Imagio ( IUS+OA )) individually and overall. There is a formal 
hypothesis test for the primary endpoint  and the three  secondary endpoin ts. Hierarchical testing 
will be in place to control the Type I error.  Truth (determination of malignant biopsy, benign 
biopsy, HR or TPB) will be taken from the PIONEER  Pivotal Study .  All CB masses (n=29) will 
be excluded from al l analyses; these masses  will  be replaced in order to preserve final analysis 
power.   
The specificity advantage of  Imagio ( IUS+OA ) vs. IUS will be compared at fixed 98% 
sensitivity. The software package OR -DBM MRMC [Version 2.5 or later] will be used for 
this analysis of OA gain  as interpolated from the ROC curves.  
Specificity and sensitivity will be calculated by reader and overall for IUS, Imagio ( IUS+OA ), 
and the pairwise difference [PROC GENMOD, see Table 1]. Specificity and sensitivity will be 
calculated using the 2% POM cut off for IUS and for IUS+OA; and then for 1%, 3%, 4%, 5%, 
6%, and 7% cutoffs to assess robustness.   In clinical practice, the POM Scores (0 -100) are 
standardized such that a BI -RADS 3 (probably benign) shows a likelihood of cancer to be > 0% 
up to 2% inclus ive. 
Specificity and sensitivity are calculated using this fixed 2% cutoff.  Please be assured that the 
OR-DBM MRMC 2.51 (Hillis) software does not pick or use a fixed cutoff.  In our application, 
the Hillis  software computes AUC, partial AUC, specificity gain at fixed sensitivity, and 
sensitivity gain at fixed specificity using a full factorial ANOVA incorporating terms for readers, 
masses, and modalities.  The gain in specificity can be computed at a wide range of sensitivities.  
The 98% sensitivity correspond s to a 2% false negative (FN) rate, but this unrelated to the use of 
a fixed 2% POM cutoff for clinical decision making.     
NLR and PLR will be analyzed using the logarithmic transformation and the delta method.    
Calculations will be performed using MAT LAB script: DLRATIOS.M.  The DLRATIOS routine 
Statistical Analysis Plan 
04 November 2019 V5  
Page 16 of 32 computes the standard deviation for the ratios of two independent random variables 
corresponding to the sensitivity and specificity which are both used to compute NLR and DLR.  
Last, pAUC  for fixed 95% to 100% sensitivity will also be analyzed using OR -BDM MRMC. 
The sample size for the R EADER -02 pivotal study was calculated using method implemented 
in the MRMC Sample Size Program 1.0 for Diagnostic Studies, by Hillis, Obuchowski, and 
Birnbaum. These sample size results may be confirmed by other packages such as nQuery, 
PASS, and SAS [PROC POWER] . 
POM summary statistics for IUS , Imagio ( IUS+OA ), and the pairwise difference will be 
displayed by diagnostic category and compared using a Wilcox on Rank Sum test . POM scores 
for benign masses will be displayed for masses with and without mammograms.  
OA feature scores including internal total, external total, and overall total scores will be 
summarized to describe the distribution of individual feat ure scores by diagnosis, with a 
Wilcoxon statistical test for the difference in the distributions between malignant and benign. 
Feature scores for benign masses will be displayed for masses with and without mammograms.  
2.1.11.1. Adjustments for  Covariates  
No adjustments for covariates are planned.  
The primary and secondary endpoints will be rerun for the subgroups with and without 
mammograms.  
2.1.11.2. Handling of Dropouts or Missing  Data  
Missing reader data will be reported (see protocol deviations). No imputation is planned for 
any excluded study data. The analysis methods can accommodate missing reader data.  
2.1.11.3. Interim Analyses and Data  Monitoring  
Plan  
The interim analysis (IA) is to re -estimate sample size to avoid running an underpowered 
study. The IA will be performed by an unblinded statistician familiar with the study data. The 
Sponsor and all other parties will remain blinded to the results.  The only communication to 
the Sponsor will be the final sample size recommendatio n.  The sample size may be increased 
up to 840 masses from the initial 480 masses in order to achieve 80% power for the primary 
endpoint. This recommendation will be based solely on variance parameters re -estimated in 
the IA (but not the effect size). Thus , these IA results fall into the category of non -
comparative results.  Thus, the IA has negligible effect on the Type 1 error.  The IA will be 
based on the total variance estimate (inclusive of both reader and imaging modality variations) 
so the IA remains  'non-comparative' since the interim treatment effect was not used to 
compute the final sample size.  
Methodology  
The sole IA goal is to compute the final sample size based on the primary endpoint.  The 
sample size re -estimation (SSRE) will be performed wit hout any adaptation.  SSRE will be 
conducted to detect the 10% absolute advantage in specificity for fixed 98% sensitivity, given 
that this is an established criterion agreed upon with FDA.  The standard deviation (from 
reader as a random effect) is not kn own.  There will be no preplanned or performed 
Statistical Analysis Plan 
04 November 2019 V5  
Page 17 of 32 assessments for futility, stopping for early efficacy, dropping readers, altering the 10% effect 
hypothesis, or any other adaptation.  Therefore, this is classic SSRE.  
Huang and Chen (1) reference this application as distinct from his discussion of adaptive 
designs.  Our IA is based entirely on non -comparative data, that is, no information about 
treatment effects were incorporated into the decision process.  For this SSRE situation (a non-
comparative interim), it can be shown that performing analyses at the conventional one -sided 
0.025 significance level has a negligible effect on the Type 1 error probability (FDA Guidance 
on Adaptive Trials (2), Wittes (3), Kieser and Friede (4), Fried e and Kieser (5), among 
others).  Wittes advises that the alpha spend is small when the observed variance is less than 
the assumed variance (as per the interim analysis) without accounting for imaging modality.  
Huang and Chen advise that the alpha spend i s small when the conditional power exceeds 
60% which is the case when a 10% delta is assumed; any delta effect would further reduce the 
reader variance.  They s pecifically state that “ for conditional power within a range of 0.37  and 
0.80, the sample size c an be increased while leaving the critical test value unchanged ”; this is 
the fundamental premise of the promising zone.  Thus, the alpha spend for conducting the 
planned interim analysis is small.  
From a testing perspective, the conclusions should hold i n recognition that the p -value is a Z-
score whether derived from a one -sample or a two -sample test independent of the model used 
(Huang or Hillis).  All alpha adjustment depends on a linear combination of Z -scores (6) for 
respective Z -scores prior to and a fter the pre -planned interim analysis.  Thus, first principles 
all lead to the conclusion that the alpha spend is small enough to ignore.  Our estimate is that 
the alpha spend is no more than 0.01% under the given conditions.  The minimal alpha spend 
deriv es from the abundant two -sample literature to apply to our paired sample setting with no 
published literature.    
Timing  
A blinded interim analysis is planned for this study after all readers complete the reads for the 
first three blocks (360  - 10 CB masse s = 350 complete image sets).   The CB masses (n=10) 
will be excluded from the interim analyses.  
The interim analysis will solely re -estimate sample size based on the primary endpoint; it will 
not be used to modify the alternative hypothesis. Neither futili ty nor efficacy will be assessed.   
The following recommendations will be issued to Seno by the unblinded statistician at the 
interim timepoint:   
1.Sample Size  Calculation:
___One  additional  block  (480 masses)  is required  OR 
___Two  additional blocks  (600 masses)  are required  OR 
___Three  additional  blocks  (720 masses)  are required  OR 
___Four  additional  blocks  (840 masses)  are required OR 
___Four additional blocks  (840 masses)  are not sufficient but  reads should continue because 
there is a reasonable chance to reach statistical significance based on the conditional 
power assuming the alternative hypothesis holds.  
___Four additional blocks  (840 masses)  are not sufficient, reads should not continue    
      because there is not a reasonable chance to reach statistical significance  
Statistical Analysis Plan 
04 November 2019 V5  
Page 18 of 32       based on the conditional power assuming the alternative hypothesis holds  
Execution  
The unblinded biostatistician will only evaluate the overall standard deviation  which was the nuisance 
parameter driving sample size for the fixed 10% difference to be detected.  The unblinded 
biostatistician will not need to take the observed delta into account.  Other than the preplanned sample 
size calculation to determine the remaini ng blocks required to complete the study, no other information 
will be revealed to the Sponsor or to any other members of the analysis team.  The IA will be executed 
to the blinded principle.  
2.1.11.4. Multiple Comparisons /  Multiplicity  
To extend labelin g claims beyond the primary endpoint, a  hierarchical testing strategy will be used to 
control Type 1 error associated with testing the primary endpoint and three secondary endpoints in the 
following pre -defined order until statistical significance is no lo nger reached in support of extended 
labeling:  
•Increase in specificity for fixed 98% sensitivity.
•Decrease in NLR
•Increase in PLR
•Increase in pAUC over 95% to 100% sensitivity
No other  endpoints are to be included as labeling claims .  
2.1.11.5. Examination of  Subgroups  
Study endpoints for benign mases with and without mammograms will be presented.  
2.1.1 2 Evaluating the  SenoGram  
SenoGram evaluation is divided into 1) evaluation of reader utilization, and 2) correctness of 
the SenoGram prediction.  Evaluation of reader utilization includes the following analysis:  
•N (%) masses with reader reporting that SenoGram increased their confidence in their
assigned BI -RADS  category.
•N (%) masses with reader reporting that SenoGram decreased their confidence i n their
assigned BI -RADS  category.
Evaluation of correctness of SenoGram predictions will be based on the analysis listed in Table 
1. 
2.1.1 3. Safety  Evaluation  
2.1.1 3.1. Extent of  Exposure  
OA Exposure for subjects in this study will be reported as was done in the. PIONEER CSR.  
2.1.1 3.2. Adverse  Events  
Adverse Events for subjects in this study will be reported as was done in the. PIONEER CSR.  
2.1.1 3.3. Clinical Laboratory  Evaluation  
Statistical Analysis Plan 
04 November 2019 V5  
Page 19 of 32 No clinical laboratory evaluations are made in this study.  
No vital si gns, physical findings, and other safety observations are made in this study.  
2.2. Hypotheses to be  Tested  
See protocol Section 10.2 for the formal hypotheses to be tested.  
2.3. Determination of Sample  Size 
See protocol Section 10.2 for the sample size justification . 
3. CHANGES  IN THE  CONDUCT  OF THE  STUDY  OR PLANNED
ANALYSES
None . 
4. REFERENCES :
1.Huang Z, Samuelson F, Tcheuko T, Chen W.  Adaptive Design in Multi -
reader Multi -case Clinical Trials of Imaging Devices. Statistical Methods in
Medical Research, 0(0) 1 -20
2.Adaptive Designs for Clinical Trials. September 2018.
3.Wittes J, Brittain E. The Role of Internal Pilot Studies in Increasin g the
Efficiency of Clinical Trials. Statistics in Medicine, 9, 65 -72, 1990.
4.Kieser, M., Friede, T. (2003). Simple procedures for blinded sample size
adjustment that do not affect the type I error rate.  Statistics in Medicine
22:3571 -3581.
5.Friede T, Kiese r M. Sample Size Recalculation in Internal Pilot Study
Designs: A Review. Biometrical Journal. 48, 4, 537 -555, 2006.
6.Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses.
Biometrics. 1994 Dec; 50 (4): 1029 -41.
7.Dorfman DD, Berbaum KS,  Metz CE (1992). Receiver operating
characteristic rating analysis: Generalization to the population of readers and
patients with the jackknife method. Investigative  Radiology, 27,  723-731.
8.Obuchowski NA, Rockette HE (1995). Hypothesis testing of diagnosti c
accuracy for multiple readers and multiple tests: An ANOVA approach with
dependent observations. Communications in Statistics -Simulation and
Computation, 24, 285 -308.
9.Hillis SL, Obuchowski NA, Schartz KM, Berbaum KS. (2005). A
comparison of the Dorfman -Berbaum -Metz and Obuchowski -Rockette
methods for receiver operating characteristic (ROC) data.  Statistics in
Medicine, 24, 1579 -1607 DOI:10.1002/sim.2024.
10. Hillis SL. (2007). A comparison of denominator degrees of freedom for
multiple observer ROC analysis.  Statistics in Medicine, 26:596 -619
DOI:10.1002/sim.2532.
11. Hillis SL, Berbaum KS, and Metz CE. (2008). Recent developments in the
Dorfman -Berbaum -Metz procedure for multi -reader ROC study analysis.
Statistical Analysis Plan 
04 November 2019 V5  
Page 20 of 32 Academic Radiology, 15, 647 -661. DOI:10.1016/j.acra.2007.12 .015B 
12. Hillis SL, Obuchowski NA, Berbaum  KS. (2011) Power estimation for
multi -reader ROC methods: An updated and unified approach. Academic
Radiology; 18:129 -142. doi: DOI: 10.1016/j.acra.2010.09.007.
13. Multi -Reader Sample Size Program for Diagnostic Studies, available at
http://perception.radiol ogy.uiowa.edu/Software/PowerandSampleSizeEstimat
ion/tabid/25 2/Default.aspx.M
14. Nofuentes  JA and de Dios Luna del Castillo J. Comparison of the likelihood
ratios of two binary diagnostic tests in paired designs. Statistics in Medicine;
Volume 26, pages 4179 -4201 March 2007.
APPENDIX  1:  OR USER MANUAL SECTION 9  
APPENDIX 2:  SAMPLE OUTPUT FOR  SPECIFICITY ADVANTAGE 
SUMMARY OF CHANGES:  
Version  Date  Description of Changes  
1.0 02May19  Original SAP  
Statistical Analysis Plan 
04 November 2019 V5  
Page 21 of 32 V 2.0  01Jul 19  START V2.0  
•Signature Page:  Roger Aitchison title change to Sr. Biostatistician, Tom
Stavros Title Change to Chief Medical Officer
•Table of Contents:  Administrative Changes  including addition of
Appendix 1 and 2
•Acronyms:  Administrative additions
•Section  2.1.1: Number 2:  Removal of “ dated March  4, 2019 - Version
1.0, subject to modification following a forthcoming FDA submission.”
•Section 2.1.1: Removal of number 4, “This document number is PROT -
00000120.”
•Section 2.1.1: Addition of new number 7 “ The image sets for this study
will come from the PIONEER Pivotal Study. Image sets are constructed
from existing mass -specific images (mammography plus ultrasound and
opto-acoustics, alone and in combination). Image sets will be allocated
for training, testing, and image set reads. Image sets previously used for
testing or training will remain for testing and trainin g. In contrast, image
sets used for the READER -02 study must not have been previously used
for testing or training. No READER -02 study image sets will be used for
SenoGram (SG) algorithm training; it is estimated that at least 840 image
sets will be availa ble for reads and remaining (~900) image sets will be
available for SG training.”
•Section 2.1.1:  Number 8: Addition  to first bullet point:  “which reflects
real world clinical practice.”
•Section 2.1.1: Number 8: Addition to t hird bullet: Addition of “in
accordance with the imaging core lab quality assurance process.”
•Section 2.1.1: Addition of new n umber 9:  “Within the Imagio
(IUS+OA) test arm of the study, each study reader will view the
SenoGram (SG) following the scoring of the IUS and OA feature score s
after viewing the IUS+OA images. The POM and BI -RADS data
collected after the SG viewing will be referred to as IUS+OA in the
remainder of this document. ”
•Section 2.1.1: Addition of language to old number 8 to new Number 10:
“The primary endpoint is to e valuate the gain in specificity at fixed 98%
sensitivity for IUS+OA post vs IUS according to a formal hypothesis test
to detect a 10% absolute advantage with 80% power. The differences
that can be detected with 80% power will also be computed for each of
the secondary endpoints (partial ROC AUC, downgrades, and upgrades);
the calculations will not be performed for either sensitivity and
specificity to avoid misinterpretation relative to the primary endpoint
(which already evaluates the specificity advantage  for fixed sensitivity).”
•Section 2.1.1: Number 13: Cui language removed related to alpha spend
Statistical Analysis Plan 
04 November 2019 V5  
Page 22 of 32 and the following language added: “The method of Chen will be 
considered to reassess the sample size; under no circumstances will the 
alternative hypothesis be modified as a result of this analysis.”  
•Section 2.1.1: Number 16 added:  “For completeness, the differences
which can be detected with 80% power will be calculated for each
primary and secondary endpoint with the exception of sensitivity and
specificity. C linically meaningful differences follow  a. partial ROC
AUC: a 0.005 difference (for 95 -100% sensitivity) b. downgrades: a
10% advantage, and c. upgrades: rule out a 5% disadvantage. ”
•Section 2.1.3 Wording added “ BBRF stratified by diagnosis, original
site CDU BI -RADS, and whether the mammogram  images were
available in selecting the masses at random from the universe of
qualified masses analyzed in the PIONEER Pivotal Study. The Sampling
Plan depends solely upon clinical study and statistical criteria, including
input from the FDA. SenoGram perf ormance was not considered and
had no impact on the plan, nor was the SenoGram development group
involved. The masses to be sampled excluded masses used in the
READER -01 study as well as masses used for training and testing
readers. The sampling strategy r eflected the overall benign mass
(including high risk masses) and malignant mass distribution in the
PIONEER Pivotal Study. When subjects had multiple masses, only the
only first mass was considered. Blocks of 120 were constructed to
include 75 benign mass es (including 3 high risk mases) plus 45 cancer
masses according to the stratification noted above.”
•Section 2.1.3  Wording Added  re: protocol deviations “Technical
protocol deviations such as a system error which would not allow the
SenoGram to be viewe d or a technical issue that will not allow an image
to be viewed by a reader will be handled during a Protocol Deviation
Meeting prior to the interim and final analysis. If an image display issue
occurs, then that case will be re -presented to a reader once  the technical
issue is corrected. If the SenoGram would not display to a reader, that
case would be excluded from the analysis. Finally, readers not
completing all reads (i.e. due to illness or family emergency) for non -
study related reasons will be repla ced by one of the pre -determined five
back -up readers as necessary. Seno will not have access to any data from
readers that did not complete all reads. No reader will be excluded as an
outlier.”
•Section 2.1.7 was rewritten to state: “The following approach es (Hillis
OR-DBM MRMC 2.51) were used to treat readers as correlated and as
random effects in analyses. See Appendix 1 for OR User Manual Section
9 for the underlying models and corresponding variance component and
degree of freedom equations including no tations. Analyses for three
study designs are presented in Appendix 2 from the READER -01
analyses for the following scenarios with primary focus on the standard
modality -by-reader -mass factorial study design, where each reader reads
Statistical Analysis Plan 
04 November 2019 V5  
Page 23 of 32 all masses for both dia gnostic tests. See Attachment 1 for discussion on 
using GEE to estimate specificity in SAS using READER -01 data. 
Analysis 1 treats both as random, and thus results generalize to both the 
population of readers and cases – this is the situation for which the  DBM 
and Obuchowski -Rockette (OR) procedures were originally designed. 
However, within the OR/DBM analysis framework one can also analyze 
the data treating only cases as random (Analysis 2) or readers as random 
(Analysis 3), although we note that these ana lyses are not unique to 
OR/DBM. For all three analyses, the null hypothesis of equal treatments 
is tested in part (a), diagnostic test difference 95% confidence intervals 
are given in part (b), and individual diagnostic test two -sided 95% 
confidence interv als are given in part (c) of the output. For the DBM 
procedure, parts (a) and (b) are based on the diagnostic test x reader x 
mass ANOVA of jackknife pseudo -values while part (c) is based on the 
reader x case ANOVA of jackknife pseudo -values for the specif ied 
diagnostic test. For the OR procedure, parts (a) and (b) are based on the 
diagnostic test x reader ANOVA of reader -performance outcomes (e.g., 
AUCs) while part (c) is based on the reader ANOVA of reader -
performance outcomes for the specified diagnostic  test. These ANOVA 
tables are displayed before the analyses. Different denominator “error 
terms” (these are the denominators used for the F statistics) are used as 
indicated for parts (a), (b), and (c) according to whether reader and case 
are treated as fi xed or random factors, and their formulas are provided in 
the output. Note that the diagnostic test confidence intervals in part (c) 
are based only on the data for the specified diagnostic test, rather than 
the pooled data. Diagnostic test difference 95% c onfidence intervals for 
each reader are presented in part (d) of Analysis 2: for DBM each 
interval is based on the diagnostic test x mass ANOVA table for the 
specified reader; for OR each interval is based on the OR variance and 
Cov1 estimates computed sep arately for each reader.  
•Analysis 1: Analysis 1 treats both readers and masses as random
samples. Results apply to the reader and mass populations — this is the
situation for which DBM and OR were initially created.
•Analysis 2: Analysis 2 treats only mas ses as a random sample. Results
apply to the population of masses but only for the readers used in the
study. For this analysis, inferences are based on the estimated error
covariance matrix, treating readers as fixed. These two methods will give
almost th e same results for typical studies where the total number of
cases is at least moderate (≥ 50). Diagnostic test differences and two -
sided 95% confidence intervals are presented for each reader in part (d).
•Analysis 3:  Analysis 3 treats only readers as a  random sample. Results
apply to the population of readers but only for the masses used in this
study. These results are based on a conventional diagnostic test x reader
ANOVA for the AUCs (or other measures), where reader is a random
factor and diagnostic  test is a fixed factor which is included for
Statistical Analysis Plan 
04 November 2019 V5  
Page 24 of 32 completeness. This is the same as a repeated measures ANOVA where 
diagnostic test is the repeated measures factor, i.e., readers provide an 
outcome (e.g., AUC) for each diagnostic test. For two tests, this anal ysis 
is equivalent to a paired t test performed on the reader -specific AUC 
estimates. DBM and OR give the same results here, and it does not 
matter with error covariance method is used with OR because the 
covariance does not enter into the F statistic. See  the respective 
equations for variance components and degrees of freedom (DF) in 
Appendix 1:  
•Section 2.1.18 Table 1 from Section 2.1.17 SAP v1 moved to Section
2.1.8 and language added under Primary Gain in Specificity endpoint  re:
Obuchowski and Rockette  (OR).  “Effect estimates (two -sided 95% CIs)
will be derived using OR -DBM MRMC methods.”
•Section 2.1.8  Secondary Endpoint for Sensitivity and Specificity
clarification language added “Specificity is defined using the percent
with a negative result (POM < 2%) among all benign+TPB masses to
include all high-risk masses. Sensitivity is defined using the percent with
a positive result (POM >2%) among all malignant masses. High risk
masses will be included in the calculations for specificity. ”
•Section 2.1.8 Sec ondary Endpoint:  Downgrade/Upgrade Endpoint s
removed
•Section 2.1.8 Exploratory Endpoin t Added:  “Inter -reader variability
assessments (POM, BI -RADS, OA feature scoring): • Mammogram •
IUS • OA.  Kappas will be calculated to assess inter -reader variabilit ies.”
•Section 2.1.9 First paragraph on primary endpoint alpha spend the “(see
Chen)” was added.
•Section 2.1.9 Downgrade Upgrade language was removed
•Section 2.1.9 “ and considering the Chen R program” was added to third
to last paragraph on sample size.
•Section 2.1.9.4:  Multiple Comparisons/Multiplicity:  The following
language was added:  “There is no alpha -splitting or hierarchical testing
plan. Additional endpoints are not to be included as labeling claims.”
•Section 3:  The following wording was added  “If the Chen R program
gives the same answers as the Hillis software, then we will consider
using the software at the time of the interim analysis.”
•Section References:  The following reference added “Chen W, Huang Z,
Samuelson F, Tcheuko L (2019). Adapti ve sample size reestimation in
MRMC studies, SPIE 10952, Medical Imaging: Image Perception,
Observer Performance, and Technology Assessment, 109520G
•Section References: The reference to Cui was removed.
•Appendix 1 added:  OR USER MANUAL SECTION 9
Statistical Analysis Plan 
04 November 2019 V5  
Page 25 of 32 Version  Date  Description of Changes  
•Appendix  2 added:  SAMPLE OUTPUT FOR SPECIFICITY
ADVANTAGE
•Various administrative changes
END OF V2.0  
Statistical Analysis Plan 
04 November 2019 V5  
Page 26 of 32 V 3.0  13Aug2019  START of V3.0  
•Acronyms:  BBRF was added
•Section 2.1.1: Number 10:  Sentence was modified to remove downgrade
and upgrade language and ROC.  It reads   …f or the secondary endpoint
“(partial AUC [pAUC]); the calculations will not be performed for either
sensitivity or specificity to avoid misinterpretation relative to the
primary endpoint (which already evaluates the specificity advantage for
fixed  sensitivity
•Section 2.1.1: Number 14: “Reader -01” was added for clarification
•Section 2.1.1: Number 15: Was revised to read “ For completeness, a pre -
defined subset of the PIONEER Study tables and listings will be
regenerated for the subset of 480 to 840  masses using the READER -02
pivotal study data.”
•Section 2.1.1: Number 16: Removed letters a,b,c related to partial
ROC:AUC, downgrades and upgrades.  Is now worded as: “ For
completeness, differences which can be detected with 80% power will be
calculated f or the primary endpoint (specificity gain at 98% sensitivity)
and for the secondary endpoint (pAUC for the sensitivity range of 95 -
100%).”
•Section 2.1.5: “Last sentence was revised to “Summary tables will
display demographic and baseline characteristics by  diagnostic status
(benign+TPB, cancer); TPB were the masses without biopsy which were
declared to be Truth Panel Benign; high risk masses will be included
with the benign masses.”
•Section 2.1.7:  Analysis 1 section: “Our planned analysis (Analysis 1)
treats both readers…”
•Section 2.1.8: Table 1: Secondary: Partial AUC clarified “Partial AUC:
Difference (Imagio (IUS+OA) vs. IUS) in partial Receiver Operator
Characteristic (ROC) Area Under the Curve (AUC) for 95 -100%
sensitivities using the OR methods. Diffe rences will be absolute
differences (|pAUC(IUS) - pAUC(OA+IUS) with no normalization. ”
•Section 2.1.8 Table 1: Secondary: Analysis/Software: Partial AUC:
MRMC & methods as per McClish removed.
•Section 2.1.8 Table 1: Secondary : Analysis/Software : Sensitivity  and
Specificity methods clarified to be “SAS PROC GEE and MIXED
treating masses as independent observations and readers as correlated
and then readers as independent and masses as correlated .”
•Section 2.1.8 Table 1: Secondary: Analysis Software: Sentence on
Confidence Intervals modified to read “Confidence intervals will be
constructed treating masses as independent observations with readers as
correlated and then readers as independent with masses correlated.
Statistical Analysis Plan 
04 November 2019 V5  
Page 27 of 32 Version  Date  Description of Changes  
•Section 2.1.8: Table 1: Secondary: SenoGram Performance: Item c
removed McClish
•Section 2.1.8: Table 1: Exploratory: Analysis /Software: OA Feature
Score Analysis and Software modified to: “ Use a Wilcoxon Rank Sum
test”
•Section 2.1.8: Table 1: Exploratory:  BI-RADS removed from Inter -
Reader variability assessments
•Section 2.1.8: Table 1: Exploratory: Analysis /Software:  Inter -reader
variability modified to “Intraclass correlation coefficient (ICC) statistics
will be calculated to assess inter-reader variabilities.”
•Section 2.1.9:  Analsyes: “(see Chen)” added to first paragraph
•Section References: Added Number 10 reference “Statistical Assessment
Methodology for Diagnostics and Biomarkers:
https://www.fda.gov/medicaldevices/  cdrh-research -Programs/statistical -
assessment -methodology -diagnostics -and-biomarkers
https://github.com/DIDSR/iMRMC/releases”
•Various administrative changes
END OF V3  
Statistical Analysis Plan 
04 November 2019 V5  
Page 28 of 32 V 4.0  23Sep2019  START of V4.0  
•Section 2.1.1: Clarification to SAS software: “version 9.3”
•Section 2.1.1: Number 7: Revised to read: “Image sets previously used
for reader testing or training will remain for testing and training. Image
sets used for the READER -02 pivotal study were not previous ly used for
reader testing or training. No READER -02 study image sets will be used
for SenoGram (SG) or Color Balance algorithm training. It is estimated
that at least 840 image sets will be available for reads and remaining
(~900) image sets will be avail able for SG training.”
•Section 2.1.1: Number 8: High Risk language removed “ DCIS,
lymphoma, or phyllodes masses” and replaced with “atypical ductal
hyperplasia, atypical lobular neoplasia, and lobular carcinoma in situ”
•Section 2.1.1:  Added new Number 9 “  Color balance (CB) masses
(n=29) used to tune the Color Balance Algorithm will be replaced for the
final analyses.”
•Section 2.1.1: Number 11: Wording removed “ the calculations will not
be performed for either sensitivity or specificity to avoid
misinter pretation relative to the primary endpoint (which already
evaluates the specificity advantage for fixed sensitivity).”
•Section 2.1.1: Number 14:  Modified to read “A blinded interim analysis
is planned after all readers complete the reading of the first t hree blocks
(360 -10 Color Balance = 350 image sets). The interim analysis will only
assess the reader variability associated with the primary endpoint; the
sample size may be left at 480 image sets or increased up to 840 image
sets based solely on the var iability determined from the primary
analysis.”
•Section 2.1.1: Number 16 was added  “Effectiveness analyses (interim
and final) will be performed without the CB cases as the primary
analysis. The interim analysis will be based on 350 masses without
replace ment while the final analysis will be based on the sample size to
be determined to potentially include all or some of the 29 replacement
cases.”
•Section 2.1.1: Number 19 was added: “A hierarchical testing strategy
will be implemented to extend labeling by testing effectiveness in the
following order: gain in specificity for fixed 98% sensitivity, NLR, PLR,
and pAUC over 95% to 100% sensitivity.”
•Section 2.1.2:  Added last sentence: “Biopsy -confirmed high -risk masses
will be included and will be classified a s benign for purposes of
effectiveness calculations.”
•Section 2.1.7: Last sentence of third paragraph added for clarification
“Analyses 2 and 3 are viewed as supportive analyses while Analysis 1 is
Statistical Analysis Plan 
04 November 2019 V5  
Page 29 of 32 viewed as the primary analysis approach.”  
•Section 2.1.7: L ast sentence of second paragraph prior to Analysis 1
modified to: “These ANOVA tables are displayed in Appendix 2.”
•Section 2.1.8: Secondary: Under Partial AUC the following sentence
was removed: “ Differences will be absolute differences (pAUC(IUS) -
pAUC( OA+IUS) with no normalization.”
•Section 2.1.8:  Inter -reader variability: Analysis/Software: Inter -reader
variability modified to read “Statistics will be calculated to assess inter -
reader variabilities.”
•Section 2.1.9: First paragraph modified to “As for  the PIONEER Pivotal
Study, analyses will be based on independent readers for POM, BI - 
RADS and feature scores (IUS, Imagio (IUS+OA)) individually and
overall. There is a formal hypothesis test for the primary endpoint and
the three secondary endpoints. Hi erarchical testing will be in place to
control the Type I error. Truth (determination of malignant biopsy,
benign biopsy, HR or TPB) will be taken from the PIONEER Pivotal
Study. All CB masses (n=29) will be excluded from all analyses; these
masses will be  replaced in order to preserve final analysis.”
•Section 2.1.9:  Language added on NLR, PLR and pAUC “NLR and
PLR will be analyzed using the logarithmic transformation and the delta
method. Calculations will be performed using MATLAB script:
DLRATIOS.M. The  changes in NLR and PLR correspond to the 10%
specificity gain for the primary endpoint. Last, pAUC for fixed 95% to
100% sensitivity will also be analyzed using OR -BDM MRMC.”
•Section 2.1.9: Language removed on considering Chen R program
•Section 2.1.9.3:  Language to account for color balance added as well as
new paragraph clarifying intent of interim analysis: “A blinded interim
analysis is planned for this study after all readers complete the reads for
the first three blocks (360 - 10 CB masses = 350 comp lete image sets).
The CB masses (n=10) will be excluded from the interim analyses.”  The
interim analysis will solely re -estimate sample size based on the primary
endpoint; it will not be used to modify the alternative hypothesis. Neither
futility nor effi cacy will be assessed. The following recommendations
will be issued to Seno by the unblinded statistician at the interim
timepoint:
1. Sample Size Calculation:
___One additional block is required OR  
___Two additional blocks are required OR  
___Three additional blocks are required OR 
___Four additional blocks are required OR  
Statistical Analysis Plan 
04 November 2019 V5  
Page 30 of 32 Version  Date  Description of Changes  
___Four additional blocks are not sufficient  but reads should continue 
because there is a reasonable chance to reach statistical significance based 
on the conditional power assuming the alternative hypothesis holds.  
___Four additional blocks are not sufficient, reads should not continue  
because th ere is not a reasonable chance to reach statistical significance 
based on the conditional power assuming the alternative hypothesis holds.  
•Section 2.1.9.4 was modified to: “To extend labeling claims beyond
the primary endpoint, a hierarchical testing stra tegy will be used to
control Type 1 error associated with testing the primary endpoint
and three secondary endpoints in the following pre -defined order
until statistical significance is no longer reached in support of
extended labeling:
• Increase in spec ificity for fixed 98% sensitivity.
• NLR
• PLR
• pAUC over 95% to 100% sensitivity
No other endpoints are to be included as labeling claims.  
•Section 3:  The following sentence was removed: “If the Chen R
program gives the same answers as the Hillis so ftware, then we will
consider using the software at the time of the interim analysis.”
•Section References: Chen reference number 1 was removed: “ 1. Chen
W, Huang Z, Samuelson F, Tcheuko L (2019). Adaptive sample size
reestimation in MRMC studies, SPIE 1095 2, Medical Imaging: Image
Perception, Observer Performance, and Technology Assessment,
109520G”
•Section References: Reference 10 was removed: 10. Statistical
Assessment Methodology for Diagnostics and Biomarkers:
https://www.fda.gov/medicaldevices/  cdrh-research -Programs/statistical -
assessment -metho dology -diagnostics -and-biomarkers
https://github.com/DIDSR/iMRMC/releases
•Various administrative changes
END V4.0  
Statistical Analysis Plan 
04 November 2019 V5  
Page 31 of 32 V5 04Nov2019  START V5.0  
•Section 2.1.1: Number 19 Modified to read: A hierarchical testing
strategy will be implemented to extend labeling by testing effectiveness
in the following order: gain in specificity for fixed 98% sensitivity,
decrease in NLR, gain in PLR, and gain in pAUC over 95% to 100%
sensitivity where gain is  the difference between the OA/US and IUS
values.
•Section 2.1.4: Sample Size Calculations: Added the entire section
including the results for the variance estimates
•Section 2.1.10: Hypotheses to be Tested: Added entire section for
clarification
•Section 2.1 .11: Data Analysis:  Added language:  “In clinical practice, the
POM Scores (0 -100) are standardized such that a BI -RADS 3 (probably
benign) shows a likelihood of cancer to be > 0% up to 2% inclusive.”
•Section 2.1.11: Data Analysis:  Added language:
“Specifi city and sensitivity are calculated using this fixed 2% cutoff.  
Please be assured that the OR -DBM MRMC 2.51 (Hillis) software does not 
pick or use a fixed cutoff.  In our application, the Hillis  software computes 
AUC, partial AUC, specificity gain at fixe d sensitivity, and sensitivity gain 
at fixed specificity using a full factorial ANOVA incorporating terms for 
readers, masses, and modalities.  The gain in specificity can be computed at 
a wide range of sensitivities.  The 98% sensitivity corresponds to a 2% false 
negative (FN) rate, but this unrelated to the use of a fixed 2% POM cutoff 
for clinical decision making.”  
•Section 2.1.11: Data Analysis: Added language:
“The DLRATIOS routine computes the standard deviation for the ratios of 
two independent rando m variables corresponding to the sensitivity and 
specificity which are both used to compute NLR and DLR”  
•Section 2.1.11.3: Interim Analyses and Data  Monitoring:  Added the
entire paragraph describing the Plan, Methodology, the sub title  Timing
and the paragraph on Execution.  Also,  under Sample Size Calculations:
added number of masses to clarify blocks.
•Section 2.1.11.3 Interim Analyses and Data Monitoring: Methodology:
The following sentence was deleted “ Thus, the alpha spend for
cond ucting the planned interim analysis is small. ” And modified to:
“They specifically state that “for conditional power within a range of
0.37 and 0.80, the sample size can be increased while leaving the critical
test value unchanged”; this is the fundamental  premise of the promising
zone.  Thus, the alpha spend for conducting the planned interim analysis
is small. ”
•References:  Added the below references:
Statistical Analysis Plan 
04 November 2019 V5  
Page 32 of 32 Version  Date  Description of Changes  
Huang Z, Samuelson F, Tcheuko T, Chen W.  
Adaptive Design in Multi -reader Multi -case 
Clinical Trials of Imaging Devices. Statistical 
Methods in Medical Research, 0(0) 1 -20   
Adaptive Designs for Clinical Trials. 
September 2018.  
Wittes J, Brittain E. The Role of Internal 
Pilot Studies in Increasing the Efficiency of 
Clinical Trials. Statistics in Medicine, 9 , 65-
72, 1990.  
Kieser, M., Friede, T. (2003). Simple 
procedures for blinded sample size 
adjustment that do not affect the type I error 
rate.  Statistics in Medicine 22:3571 -3581.  
Friede T, Kieser  M. Sample Size 
Recalculation in Internal Pilot Study Designs: 
A Review. Biometrical Journal. 48, 4, 537 -
555, 2006.  
Bauer P, Kohne K. Evaluation of 
experiments with adaptive interim analyses.  
Biometrics. 1994 Dec; 50 (4): 1029 -41. 
END V5.0  